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            Topical aminolevulinate-based photodynamic therapy (ALA-PDT) is an effective 
method for treating skin lesions such as multiple actinic keratoses (AK). The major side 
effect of ALA-PDT is the pain experienced during the treatment. Management of treatment-
related pain still remains a considerable challenge in patients. Further optimization of the 
treatment protocol including light source, dose and duration therefore seems crucial to try and 
alleviate pain. Previous data from this laboratory have demonstrated that ALA-treated human 
skin fibroblasts become highly sensitive to Ultraviolet A (UVA, 320-400nm)-induced 
cytotoxicity. In the present study, we provide further evidence that ALA-PDT with UVA is 
also effective in photokilling of human skin keratinocyte HaCaT cells despite their known 
resistance to UVA. The UVA-mediated damage in ALA-treated skin cells may be due to 
rapid release of potentially harmful transit labile iron (LI) in cells that in conjunction with 
increased generation of singlet oxygen (
1
O2) and other reactive oxygen species (ROS) by 
endogenously accumulated Protoporphyrin IX (PPIX) further exacerbate the oxidative 
damage in skin cells leading to cell death. We therefore hypothesized that by using UVA as 
the light source and by fractionating the dose applied into two short pulses with 1h dark 
interval, the ALA-treated skin cells could be further sensitized to UVA-induced damage, 
since the first dose of UVA would trigger the formation of ROS and extensive release of LI 
which in turn would intensify the damage caused by the second challenge dose of UVA. By 
using a series of UVA split-dose combinations, we could demonstrate that applying short 
pulses of UVA radiation to ALA-treated skin cells is a fast and efficient way to promote cell 
death. Furthermore the results of this project highlighted the importance of the first UVA 
dose in determining the efficiency of cell killing following the second UVA dose. The critical 
role of iron in exacerbating the UVA-induced damage of ALA-treated cells was confirmed 
with experiments showing that iron loading of cells with hemin prior to ALA-treatment could 
further sensitise the keratinocytes to very low doses of UVA. The damaging effects of short 
pulses of low UVA doses following ALA-treatment can be exploited to provide a rapid mean 
to improve the effectiveness of ALA-PDT of skin lesions while reducing considerably the 
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1.1. Human Skin 
Skin is the largest organ of the body, which keeps the internal systems intact. It is not only a 
barrier to protect the body from chemical and physical (e.g. ultraviolet) agents and micro 
organisms, but is also involved in defence mechanisms and other important functions. The 
skin thickness varies depending on the site of the human body, but the average is 0.3-0.4 mm. 
The skin is composed of two layers; the upper epidermis and the inner dermis (see Figures 1 
and 2) (Bruls et al, 1984). 
 
The epidermis begins at the outer surface and works inwards. There are four clear layers that 
can be observed in the epidermis under a light microscope. They are defined as: 
1) Cornified layer - stratum corneum. 
2) Granular layer - stratum granulosum - the zone where epidermal nuclei 
disintegrate. 
3) Germinative or prickle cell layer - the bulk of living epidermal keratinocytes. 
4) Basal layer - stratum basale - the only keratinocytes in normal epidermis that 
undergo cell division (Bruls et al, 1984).  
 
The epidermis is mainly composed of keratinocytes with some Langerhans cells and 
melanocytes. Keratinocytes produce the protein keratin (which provides strength and 
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flexibility to the epidermis) and a low level of wide range of cytokines so that keratinocytes 
can influence immunologic function. These cytokines include interleukins (ILs), chemokines, 
tumour necrosis factor (TNF), colony stimulating factors (CSFs) and growth factors. 
Keratinocytes in the basal layer divide (on average every 4 weeks) and the daughter cells 
undergo changes as they move upward to the skin surface. At the final external layer (stratum 
corneum) dead cells are constantly shed, while new cells are continuously produced in the 
basal layer (Bruls et al, 1984). Langerhans cells are antigen presenting cells and play a major 
role in the immune surveillance system of the skin. Through maturation they become 
melanosomes and are then transported to the outermost layer of the epidermis. They have the 
role of forming a UV-absorbing barrier, which in turn reduces the amount of radiation that 
could penetrate the skin (Bruls et al, 1984). 
 
The middle layer of the skin is the dermis, which is a connective tissue matrix between the 
epidermis and the subcutaneous layer. The upper dermis consists of capillaries which nourish 
the epidermis, and the lower thicker layer i.e. the reticular dermis. The major cell type in 
dermis is fibroblast, which synthesize elastin, collagen and glycosaminoglycans (GAG). 
Elastin fibres provide elasticity while collagen fibres provide strength. GAG provides 
viscosity, hydration and allows the dermis‟s limited movement. Other cells embedded in the 
reticular layer include fat cells and dermal dendrocytes, mast cells, macrophages and 
lymphocytes as well as many blood and lymphatic vessels, nerves and nerve endings, oil 
glands and hair roots (Carlson, 1994) (see Figure 1). 
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Figure1. Representation of skin layers and components.  
(Modified from cancer.stanford.edu/.../tumorBiopsy.html )  
 
 Figure 2.  Representation of section of epidermal layers of skin as it can be observed under a 
light microscope. (Source: three dimensional organotypic skin culture made with normal human skin 
keratinocytes. (Aroun, Reelfs and Pourzand, unpublished data). 
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1.2. Ultraviolet (UV) Radiation 
 
1.2.1. General information 
Ultraviolet (UV) is part of non-ionising electromagnetic radiation and includes wavelengths 
ranging from 100 nm to 400 nm (Tyrrell, 1994). Exposure to UV occurs from both natural 
and artificial sources.  
The major source of natural radiation is sun. The sun emits radiation with wavelengths 
ranging from infrared (760-3000 nm) and visible (400-760 nm) to UV (190-400 nm). The UV 
component of sunlight is subdivided to UVA (320-400 nm, near-UV), UVB (290-320 nm, 
mid-UV) and UVC (190-290 nm) wavelengths (see Figure 3). Solar UV radiation comprises 
5% of the total sun radiation emission. The majority of UV radiation of sunlight is UVA 
(>95%) (Tyrrell, 1994). 
  
Figure 3. Presentation of solar electromagnetic radiation emission. The typical non- ionising 
electromagnetic source spectrum wavelength ranges from UV (UVC 190-290 nm, UVB 290-320 nm, 
UVA 320-400 nm) to visible (400-760 nm) and infrared (760-3000 nm) radiation. (Modified from 
http://www.uvabcs.com/uvlight-typical.php) 
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Figure 4. Representation of solar UV components and stratospheric ozone layer. UVC 
component of sunlight is filtered by ozone layer and cannot reach the surface of the earth. So the solar 
UV components reaching the earth‟s surface are composed of UVA and UVB only. (Modified from 
www.on.ec.gc.ca/.../tg_chap06_e.html)  
 
A number of factors such as solar zenith angle, atmospheric ozone and cloudiness can 
influence the UV intensity reaching the surface of the earth. The spectral distribution of solar 
radiation that reaches the earth‟s surface is composed of visible, UVA and UVB components. 
The stratospheric ozone layer filters the UVC component of sunlight and as a result UVC 
does not reach the earth‟s surface (see Figure 4). Therefore, the effects of solar UV radiation 
on biological systems is limited to UVA and UVB wavelengths alone (Tyrrell, 2004). 
 
1.2.2. Biological effects of solar UV radiation 
The major targets for UV in humans are the skin and the eyes and the transmission of UV 




Ozone Layer UVA UVB 
UVB 
UVC 
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Thus the longer wavelengths can penetrate deeper causing effects on targets which differ 
sharply from those of shorter wavelengths (Tyrrell, 1996). 
 
The epidermis is the primary target for oxidative stress that is generated by both the solar 
radiation and also other chemical and physical agents in the environment. The amount of 
radiation received by the two major skin cells, the epidermal keratinocytes and dermal 
fibroblasts are different. The epidermal keratinocytes are exposed to both UVA and UVB 
radiation while the dermal fibroblasts are protected from UV radiation to a considerable 
extent by the overlying epidermis and therefore mostly receive UVA radiation (Tyrrell, 1994) 
(see Figures 5 and 6). A large proportion of UVA radiation can penetrate quite deeply into 
the skin and it has been shown that 35-50% of the overall UVA component of sunlight can 
reach the dermis of caucasian skin (Bruls et al, 1984). However only a small amount of UVA 
can reach below the surface of the skin and penetrate blood vessels (see Figures 5 and 6). 
 
At cellular level, the interaction of UV with biological material changes as a function of 
wavelength and requires the absorption of the radiation by biomolecules. The UVB region 
overlaps with the DNA absorption spectrum and as a result the direct absorption of UVB by 
cellular DNA causes DNA photodamage and mutagenesis (Tyrrell, 1994; Freeman, 1989). In 
contrast, UVA is weakly absorbed by most biomolecules but is oxidative in nature, 
generating reactive oxygen species (ROS) such as singlet oxygen (
1
O2) via photochemical 
interactions with intracellular chromophores (Tyrrell, 1991; Tyrrell 1996). 
 
 







Figure 5. The depth of penetration of UV and visible wavelengths into the different layers of 
skin . The transmission of UV through skin layers increases with increase in wavelength. (Modified 
from www.pgbeautygroomingscience.com/the-sun.html).  
 
Figure 6. Penetration of solar UV radiation into the skin. UVA (320-400 nm) has a deeper 
penetration potential through the skin layers than UVB (290-320 nm).  (Reproduced from Tyrrell, 
1994 with permission) 
 
Both acute and chronic exposures to sunlight are associated with various physiological and 
pathological states. The acute response involves immediate effects including erythema, heat, 
swelling, sunburn, pigmentation, hyperplasia, immune suppression and vitamin D synthesis 
(Gasparro et al, 1998). The chronic response involves delayed effects such as cataract and 
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skin ageing (also called photo-ageing), which is the result of morphological changes such as 
wrinkling, elasticity loss, uneven pigmentation due to general alteration of all the epidermal 
and dermal components of skin. Chronic exposures of skin to UV radiation may lead to skin 
cancer (reviewed by Tyrrell, 1994; Reelfs et al, 2010). In the recent decades, there has been a 
substantial decrease in the ozone layer and as a consequence the earth is exposed to more UV 
radiation. (Schwartz, 1997) This phenomenon has had an impact on human health in the form 
of increased incidence of sun-related skin disorders notably actinic keratoses (AK) and skin 
cancer (Schwartz, 1997) Nevertheless sunlight has several beneficial effects. The sun rays 
provide us heat, light and the general feeling of well being. The sunlight also stimulates blood 
circulation and the production of vitamin D that is required for maintaining blood calcium 
levels in individuals (Schwartz, 1997; Zanolli, 2004). 
 
1.2.2.1. Biological effects of solar UVA radiation 
The short-term effects of UVA on skin include erythema (skin redness), sunburn and 
pigmentation, and long-term effects include ageing and carcinogenesis (Tyrrell, 1991; 




 fold less efficient than UVB to initiate these 
responses, as underlined by their action spectra (Parrish et al, 1982; De Gruijl and van der 
Leun, 1992). These ratios of efficiency also apply to other responses such as mutagenicity or 
lethality in cell cultures (Keyse et al, 1983; Tyrrell and Pidoux, 1987; Jones et al, 1987). 
Most of the biological effects of UVA, either on cultured cells (Danpure and Tyrrell, 1976) or 
in skin (Auletta et al, 1986) are oxygen-dependent. Taking the action spectra data, solar 
spectro-radiometric measurements and known transmission of human skin into consideration 
have made us understand that the UVA component of sunlight contributes to up to 80% of the 
cytotoxic action of sunlight at the basal layer of epidermis (Tyrrell and Pidoux, 1987). Indeed 
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the greater histological effect of UVA is relatively observed on the dermis than on the 
epidermis for that for UVB.  Human skin showed decreased permeability on the barrier of the 
stratum corneum when exposed to UVA (McAuliffe and Blank, 1991). UVA also depletes 
epidermal Langerhans cells, and recruits neutrophils into irradiated skin (Gilchrest et al, 
1983).  
At cellular level, UVA has been shown to cause lipid peroxidation at biologically relevant 
doses in the membrane of human cultured fibroblasts (Tyrrell, 1996). UVA-induced lipid 
peroxidation was found to be dependent on the “chemical” composition of membranes, as 
polyunsaturated fatty acid enrichment of human keratinocytes increases the peroxidation 
process (Quiec et al, 1995). Peroxidised membranes in cultured human skin keratinocyte tend 
to lose their fluidity following UVA irradiation. This suggested that loss of membrane 
integrity and selective permeability might result in alteration of transport systems, as well as 
the leakage of essential components or influx of extracellular molecules such as calcium and 
toxins. 
This concept was backed up by the findings that UVA radiation inhibited in a dose-dependent 
manner both receptor-mediated and non-specific uptake of exogenous molecules (Djavaheri-
Mergny, 1993). Internal lipid membranes of eukaryotic cells (e.g. lysosomal, mitochondrial 
and nuclear) have also been shown to be damaged following UVA irradiation. The latter has 
deleterious consequences to skin cells. UVA-induced damage to lysosomes is an early event 
that leads to temporary intracellular leakage of lysosomal proteases into the cytosol which in 
turn causes the degradation of cytosolic proteins notably the iron storage protein, ferritin (Ft) 
(Pourzand et al, 1999a). The UVA-induced proteolytic degradation of Ft leads to an 
immediate measurable increase in the level of potentially harmful redox active free transit 
iron pool, known as labile iron pool (LIP). The UVA-mediated increase in LIP has been 
shown to further exacerbate the peroxidative damage in cultured skin fibroblasts (Zhong et al, 
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2004) that may lead to the loss of cell membrane integrity.  UVA also damages the 
mitochondrial membrane leading to immediate depletion of intracellular ATP. The depletion 
of cellular ATP along with loss of membrane integrity lead to necrotic cell death in irradiated 
skin cells (Zhong et al, 2004, see section 1.5.6.). Furthermore it was found that the slow 
kinetics of the induction of the nuclear transcription factor kappa B (NF-kappaB) by UVA 
relative to other oxidants is due to a transient increase in permeability of the nuclear 
membrane to proteins and occurs as a result of iron-mediated damage to the nuclear 
membrane (Reelfs et al, 2004). The apparent slow response of NF-kappaB to UVA radiation 
is likely to have consequences on the kinetics of activation of NF-kappaB target genes in the 
nucleus notably pro-inflammatory cytokines and proto-oncogenes (Tyrrell, 1996; Soriani et 
al, 1998; Reelfs et al, 2010).  
Lipid peroxidation products may also induce damage to DNA (Vaca et al, 1988) as illustrated 
by the finding that lipid hydroperoxide decomposition products induced DNA adduct in vivo 
in liver and kidney (Wang and Liehr, 1995). Therefore, mutations may arise and alter gene 
expression. 
In photodermatological studies, special attention has been given to “sunburn” keratinocytes, 
since the morphology of these cells is associated with characteristic features such as pyknotic 
nucleus and eosinophilic cytoplasm. The “sunburn” cells were first discovered in the 
epidermis of mammalian cells exposed to UVB radiation and later on regarded as an example 
of programmed cell death pathway now referred to as “apoptosis” (Weedon et al, 1979; Ley 
and Applegate, 1985; Young, 1987). This self-destructive programme became particularly 
important when it was shown that this process can eliminate pre-cancerous cells (Ziegler et 
al, 1994) and highlighted the necessity of understanding the phenomenon in order to develop 
therapeutic strategies for control of the carcinogenesis process (Barber et al, 1998). 
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Interest in the link between UV and apoptosis has increased since Godar et al (1994) 
investigated cell death mechanisms in different waveband regions of UV (UVC, UVB and 
UVA) on murine lymphoma cells. They found that all waveband regions of UV radiation 
cause apoptosis. However, UVA induced immediate (0-4h) and delayed apoptosis, whereas 
UVB or UVC induced delayed apoptosis (>20h).  Studies from this laboratory have shown 
that unlike murine cultured cells, the human skin fibroblasts and keratinocytes are quite 
resistant to UVA-induced apoptosis and upon severe UVA insult, they die mainly by necrotic 
cell death (Pourzand et al, 1997; Pourzand and Tyrrell, 1999; Zhong et al, 2004; Reelfs et al, 
2010).   
 
DNA may be a target to UVA radiation, since it absorbs, although very weakly, in the UVA 
region up to 360 nm (Sutherland and Griffin, 1981). However, in contrast to UVB, UVA 
genotoxicity is most likely induced by indirect mechanisms involving absorption of photons 
by unidentified endogenous photosensitisers and generation of ROS (see section 1.3.2.). This 
is suggested by (i) the oxygen-dependence of induction of most DNA lesions by UVA (Peak 
et al, 1987) and (ii) the fact that frequency of lesions induced by UVA does not follow the 
absorption spectrum of DNA, either in vivo (Freeman et al, 1989) or in vitro (Peak and Peak, 
1995). Lesions include mainly DNA strand breaks and protein cross-links (covalent links 
between a protein and DNA).  However, the formation of 8-hydroxydeoxyguanosine (8-
OHdG), seems to be the most important type of lesion occurring in the UVA range and has 
been shown in different mammalian cell types (Kielbassa et al, 1997; Zhang et al, 1997). 
Most importantly the damage has been shown to depend on 
1
O2 generation (Kvam and 
Tyrrell, 1997).  This is the major interest since UVA radiation of sunlight produces 
biologically relevant levels of 
1
O2 and also other ROS (Tyrrell, 1991) and the effects of UVA 
including cell inactivation are completely dependent on the presence of molecular oxygen 
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(Danpure and Tyrrell, 1976). Another type of damage, the pyrimidine dimers, has been 
shown to occur in human skin following UVA irradiation (Burren et al, 1998; Cadet et al, 
2009). 
 
Direct damage to proteins can happen at much longer wavelengths than direct damage to 
DNA. Although proteins absorb most strongly in the UVC range, as the wavelength is 
increased through the environmentally relevant UVB and UVA regions, damage to proteins 
become increasingly important relative to DNA damage because of absorption properties of 
the aromatic amino acids (tyrosine, tryptophan) which exhibit absorption that tails into UVA 
range (Vile and Tyrrell, 1995). Protein and amino acid hydroperoxides then produce various 
radicals via Fenton like reactions catalysed by iron metals, particularly ferrous iron (Neuzil et 
al, 1993; Dean et al, 1993).  
 
Haem containing proteins (including cytochromes), the antioxidant enzymes catalase and 
peroxidases are potential targets for damage by UVA. Repair enzymes have also shown to be 
sensitive to UVA radiation and there is evidence that UV-induced repair disruption plays a 
role in cell death and mutagenesis (Haynes 1966; Webb et al, 1977; Menezes and Tyrrell, 
1982). Oxidative modifications of for example collagen and transcription factors appear to 
mark them suitable for degradation in some systems (Helm and Gunn, 1986; Vince and Dean, 
1987; Pacifici and Davies, 1990) but in others inefficient catabolism of oxidised proteins 
contributes to their accumulation (Wolff and Dean, 1986; Davies, 1986; Stadtman, 1992; 
Jessup et al, 1992; Grant et al, 1992). 
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Artificial sources of UV including UVA radiation have been used for the treatment of a 
number diseases notably rickets, psoriasis, eczema and jaundice (Zanolli, 2004; Krutman, 
2000). In view of the potentially harmful effects of UV radiation, the treatments take place 
only when benefits are thought to outweigh the risks. 
 
This MPhil thesis investigates the potential of broad spectrum UVA radiation (320-400 nm) 
for photodynamic therapy of superficial skin lesions such as AK.  
 
1. 3. Oxidative stress and reactive oxygen species (ROS)   
Oxygen is by far the most abundant element in the earth‟s crust (Halliwell and Gutteridge, 
1989) Oxygen is required for all the plants and animals for the efficient production of energy, 
except those organisms that are especially adapted to live under anaerobic conditions. 
Although oxygen is essential to life, it can give rise to a variety of ROS as part of normal 
metabolism (Halliwell and Gutteridge, 1989). 
 
The term “oxidative stress” is referred to a situation in cells in which the equilibrium between 
pro-oxidant and antioxidant species is broken in favour of pro-oxidant state, due to generation 
of potentially harmful ROS (Halliwell and Gutteridge, 1989). Toxicities and pathologies 
associated with the oxidation of nucleic acids, proteins, lipids and carbohydrates have also 
been collectively termed “oxidative stress”. 
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1.3.1. Reactive Oxygen Species (ROS) 
A free radical is defined as “any atom or molecule with one or more unpaired electrons in an 
outer valence shell” (Halliwell and Gutteridge, 1989).  
 Free radicals are species capable of independent existence and contain one or more unpaired 
electrons in an orbital in the outermost electron shell. They are able to either take an electron 
from or donate an unpaired electron to another molecule. This property makes radicals very 
reactive towards their environment and therefore potentially damaging for living systems as 
they may be involved in the initiation and propagation of free radical chain reactions which 
potentially damage cells (Riley, 1994; Ryter and Tyrrell, 1998). Free radicals can kill 
bacteria, modify genomic and cellular structures, provoke immune responses, damage 
biomolecules, activate oncogenes, cause artherogenesis and enhance the ageing process 
(Halliwell and Gutterridge, 1989). 
 
At the cellular level, the primary target of free radicals is the lipid bilayer of the membrane. 
The presence of polyunsaturated fatty acids in cell membranes as well as in intracellular 
membranes of organelles such as mitochondria and lysosomes makes them highly vulnerable 
to oxidative injury that results in lipid peroxidation. Lipid peroxidation is the process by 
which a free radical chain reaction will lead to generation of fatty acid radical and 
consequently fatty acid peroxyl radical and aldehydes. The lipid peroxidation results in loss 
of cellular membrane integrity and leads to necrotic cell death (Girotti, 2001; Reelfs et al, 
2010). Free radicals can also oxidize proteins and carbohydrates (Halliwell and Gutteridge, 
1999).    
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Organic free radical species are numerous but oxygen-based free radicals which occur in 
biological systems are limited.  ROS is a collective term that includes not only the oxygen-




) and hydroxyl radical (
•
OH) but also 
non-radical derivatives of oxygen such as singlet oxygen (
1
O2) and hydrogen peroxide 
(H2O2), which are able to form radicals. (Halliwell and Gutteridge, 1999).  
 
ROS may be generated by exogenous or endogenous factors. Examples of exogenous factors 
include pesticides, ozone, photochemical smog, ionising and UV radiations. The endogenous 
mechanisms include mitochondrial respiration, microsomal and nuclear membrane electron 
transfer and phagocytic oxidative burst (Danpure and Tyrrell, 1976; Tyrrell and Pidoux, 
1989). 
 
ROS may be produced from the step by step reduction of O2 molecule to H2O as shown in  
Figure 7.  
                                  
                                    e
-
           e
-
             e
-
            e
-
 
                             O2    ·O2
-
    H2O2  ·OH    H2O 
                 2H








Figure 7: The series of four one-electron (e
-
) uptake steps when O2 is reduced to H2O. The dots in 
two species ·O2
-




O2, may also be formed as a consequence of photochemical reactions 
between light, O2 and light-reactive substances called „photosensitisers‟ (Halliwell and 
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Gutteridge, 1990; Foote et al, 1982). The UVA component of sunlight produces 
1
O2 and 
other ROS through the interaction of this penetration radiation with endogenous 
photosensitisers (i.e. chromophores) such as porphyrins in the skin (Tyrrell, 1994; Black, 
1987; Trenam et al, 1992; Yasui and Sakurai, 2000).  
 
The artificial photochemical generation of 
1
O2 and other ROS by endogenous or exogenous 
photosensitisers are used to destroy malignant cells and tissues, in a process called 
photodynamic therapy (PDT). Biological 
1
O2, however may also arise from non- 
photochemical sources such as the macrophage respiratory burst and membrane lipid 
peroxidation chain reactions (Cadenas, 1989; Krinsky, 1979).  
 
Uncontrolled production of ROS causes damage to biomolecules and may in turn lead to 
diseases. ROS have been implicated in numerous types of cell and tissue injury, cell death 
(i.e. apoptosis or necrosis), ageing, drug action, drug toxicity as well as in initiation and 
progression of a number pathologic disorders notably chronic inflammatory disease and 
cancer (Halliwell and Gutteridge, 1999; De Groot, 1994; Stohs and Bagchi, 1995; Tenopoulo 
et al, 2005; Trenam et al, 1992).  
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) is the yield of one electron reduction of oxygen. The most 




 in vivo in aerobic cells are the electron transport chains of 
mitochondria during respiration and the endoplasmic reticulum. However, phagocytic cells 




 via an NADPH oxidase enzymatic 
systems (see eqn 1a or simplified eqn 1b) as part of their defence against invading 
microorganisms (Babior, 1999).        
                                  NADPH  
                                                       Oxidase 








   eqn (1a) 
 
    O2 + e
- 
   •O2
–  
 eqn (1b) 
  




with regard to living organisms is the dismutation 
reaction (eqn 2) which produces the well known oxidant H2O2. This reaction is extremely 
slow in neutral solution (Crichton et al, 2008), but in cells it is extremely rapid due to 
catalysis by a group of enzymes, the superoxide dismutases (SODs). 
                SOD 





    H2O2 + O2
  
 eqn (2) 
 




 may also be obtained through the UVA irradiation of NADH 
and NADPH in vitro (Czochralska et al, 1984; Cunningham et al, 1985). 
 






 is relatively unreactive towards most biomolecules, including lipids and nucleic acids 
(Fridovich, 1978). On the other hand, it may react with certain proteins and inactivate them, 
notably proteins containing transition-metal prosthetic groups such as iron-sulfur clusters 
(Gardner et al, 1997).  
   




 may act as reductant as 




 is able to reduce iron from Ft to its most reactive form Fe 




 an important intermediate in 
the formation of 
•





toxicity to cells will depend largely on the availability of iron in the system. 
 
1.3.1.2. Hydrogen Peroxide (H2O2) and Hydroxyl Radical (
•
OH)  
The involvement of H2O2 in numerous types of cell and tissue injury is well-documented 
(Halliwell and Gutteridge, 1999; De Groot, 1994; Stohs and Bagchi, 1995; Tenopoulo et al, 
2005). Although H2O2 itself has low reactivity towards cell constituents, it is capable of 
forming the highly reactive 
·
OH in the presence of trace amounts of iron via the Fenton 
reaction. 
Under physiological conditions, cells protect themselves either by the H2O2 –degrading 
enzymes catalase and glutathione peroxidase (GPx) (Pourzand et al, 2000), or by maintaining 
the level of redox active LIP via the cytosolic iron regulatory proteins 1 and 2 (IRPs) which 
function as post-transcriptional regulators of both iron uptake via transferrin receptor (TfR) 
and iron sequestration by the iron storage protein, Ft (Hentze and Kuhn, 1996; Cairo and 
Pietrangelo, 2000). However under pathological conditions, these defences are often 
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insufficient, because the system is either overwhelmed by an increased H2O2 formation 
(Rosser and Gores, 1995; De Groot, 1994; Sussman and Bulkley, 1990; de Groot and Brecht, 
1991) and/or by an excess presence of labile iron (LI) (Tacchini et al, 1997). The 
simultaneous presence of excess redox active chelatable LI and H2O2 can be potentially toxic 
for cells as it can catalyze the formation of oxygen free radicals such as ·OH via the Fenton 
reaction (Halliwell and Gutteridge, 1992).  
The major source of ·OH generation is via the iron-catalysed Haber-Weiss or the Fenton 




 reduces ferric iron to ferrous state:  




    Fe2+ + O2                                         eqn (3) 
Ferrous iron then reacts with H2O2 to generate 
•
OH: 
          H2O2 +   Fe
2+






 + H2O2    
iron catalyst  O2  +  
•
OH  + 
-
OH   eqn (5) Haber Weiss reaction
 
In cells the best catalyst of Fenton reaction is the low molecular weight LI, or alternatively 
the iron made available through other cellular sources under oxidative stress conditions such 
as UVA- and H2O2-induced release of LI from Ft (Jacobs, 1977; Puppo and Halliwell, 1988; 
Pourzand et al, 1999a; Breuer et al, 1997; Yiakouvaki et al, 2006). 
The ·OH radical is more reactive than •O2
-





 and H2O2 have longer half-lives but are less reactive (Martinez-Cayuela, 1995).     
The highly reactive 
•
OH radical is capable of interacting with most biomolecules including 
sugars, lipids, proteins and nucleic acids. These interactions that promote various harmful 
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processes in cells such as lipid peroxidation, protein oxidation, DNA/RNA oxidation and 
DNA lesions, ultimately overwhelm the cellular antioxidant defence mechanisms and lead to 
cell damage and cell death (Halliwell and Gutteridge, 1992 and 1999; Kakhlon and 
Cabantchik, 2002). 
1.3.1.3. Singlet Oxygen (
1
O2) 
In vitro studies have demonstrated that 
1
O2 is a highly reactive form of molecular oxygen that 
may harm living systems by oxidizing critical organic molecules, including membrane lipid, 
protein, amino acids, nucleic acids, nucleotides, pyridine nucleotides, carbohydrates and 
thiols (Halliwell and Gutteridge., 1989). At the cellular level, the 
1
O2-mediated oxidation of 
macromolecules such as lipids could promote potentially harmful processes such as lipid 
peroxidation, membrane damage and cell death (Halliwell and Gutteridge, 1999).   
1
O2 is a derivative of molecular oxygen in which all valence electrons are spin-paired. It 
differs from ground state (triplet, 
3
O2) molecular oxygen in the reversal of the spin direction 
of one electron in the outermost valence shell. This specific electronic configuration 
illustrates its non-radical nature (Kasha and Brabham, 1979).    
1
O2 exists in two forms of ground state and a higher energy form. The high form decays back 
to ground state configuration immediately upon formation and is thus thought to be irrelevant 
to biological systems (Ryter and Tyrrell, 1998).  
The half life of 
1
O2 is longer in deuterium oxide (D2O) than in water or aqueous solution. 
Thus biological responses are often compared by replacing H2O in the system with D2O, as a 
test for 
1
O2 generation (Pourzand et al, 2000).  
As mentioned previously, 
1
O2 (and other ROS) may be generated as a consequence of 
photochemical reactions between light, O2 and light-reactive substances called 
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photosensitisers (Halliwell and Gutteridge, 1990; Foote, 1982). These include many natural 
substances such as porphyrins (hematoporphyrin and protoporphyrin IX), chlorophylls (a,b), 
bilirubin IXa, retinal (rhodopsin), quinones and flavins (riboflavin) (Spikes, 1989) The light 
might be absorbed by the photosensitiser in order to produce a chemical change. Indeed the 
first step in a photochemical reaction is the absorption of a single photon by the 
photosensitiser in the ground state (i.e. S
0
) and the production of an excited state in which one 
electron in the outermost valence shell of the absorbing photosensitiser is raised to a higher 
energy level (i.e. S
1*
) with conservation of spin direction. Because of the short lifetime of S
1*
, 
it may either decay back to S
0
 with emission of fluorescence or may be converted by 
intersystem crossing to the more stable excited triplet state (i.e. S
3*
), where the promoted 
electron in a higher orbit undergoes a spin inversion. The generated S
3*
 is sufficiently long-
lived to take part in chemical reactions and therefore the photochemical (or photodynamic) 
action takes place for the most part when in triplet state. There are two types of 
photochemical reactions. i.e. Type I and type II:   
 Type I are electron- or hydrogen-transfer reactions between the triplet photosensitiser 






OH and H2O2 and thereby returning of the photosensitiser to the ground state.  
 Type II is an electron spin exchange between the photosensitiser in S3* state and 
ground state triplet oxygen (
3
O2) resulting in the production of 
1
O2 while the 
photosensitiser returns to its ground state. 
Both type I and type II reactions cause oxidation of biomolecules in the cell but 
1
O2 is 
regarded as the main mediator of phototoxicity in PDT (Nyman and Hynninen, 2004; 
Calzavara-Pinton et al, 2007; Gomer et al, 1988; Gomer et al, 1989; Foote, 1991). Because 
the photosensitiser returns to the S
0
 state in these reactions, it can generate a manifold 
concentration of reactive intermediates. Eventually, however, the photosensitiser is degraded 
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by light forming a photoproduct. This process, known as „photobleaching‟ can results from 
reactions of type I or type II.      
  
1.3.2. UVA and ROS  
There is ample evidence that the biological effects of UVA radiation on cells are dependent 
on the presence of oxygen (Danpure and Tyrell, 1976; Tyrrell and Pidoux, 1989), implying 
the involvement of ROS in UVA-mediated cytotoxicity. UVA is weakly absorbed by most 
biomolecules but is oxidative in nature, generating oxygen intermediates through a variety of 
photosensitisers, which are referred to as „chromophores‟.  
UV must be absorbed in order to produce a chemical change. Each chromophore is 
characterised by the wavelength at which it absorbs, a property which determines its relative 
importance at each wavelength throughout the UV spectrum. Absorption of UV radiation by 
a biomolecule leads to the excitement of its electron.  The chemical modification of the 
biomolecule depends on its structure, the UV wavelength, and the conditions of the reaction 
occurred.  
UV absorption by the biomolecule may create two outcomes: 
1. Generation of reactive species in a metastable excited state. 
2. Production of free radicals. 
Both of the above are formed extremely quickly, since chemical reactions often occur within 
microseconds but may last for hours. These relatively fast processes are eventually translated 
into photobiological responses which could occur in seconds but can take years to become 
apparent (e.g. cancer).  
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OH (Tyrrell, 1991). The highly reactive 
•
OH can be generated via iron-




(Beachamp and Fridovich, 1970).  
In vivo, ROS may also be generated by UVA irradiation (Tyrrell, 1991; Beauhamp and 
Fridovich, 1970) via interaction with intracellular chromophores notably quinones, flavins, 
steroids and porphyrins, though the exact species remain to be defined (Tyrrell, 1994).  
A number of reactions capable of generating 
1
O2 under conditions relevant in vivo have been 
proposed (Badwey and Karvosky, 1980) and studies from Tyrrell‟s laboratory using either 
specific scavengers of 
1
O2 or D2O (which enhances the lifetime of this molecule) have clearly 
demonstrated the involvement of 
1
O2 in UVA cytotoxicity to mammalian cells (Tyrrell, 1991; 
Pourzand et al, 2000). UVA effects also involve H2O2 formation and iron-catalysed 
generation of 
•
OH (Tyrrell, 1991; Pourzand et al, 1999; Zhong et al, 2004; Reelfs et al, 
2010). Based on such considerations, the UVA component of sunlight is now considered as a 
generator of intracellular oxidative stress. 
Porphyrins and in particular protoporphyrin IX (PPIX) , the immediate precursor of heme in 
heme biosynthesis is thought to be a very important UVA chromophore since it possesses a 
band absorption with a peak around 410 nm that tails with the UVA range and it has the 
potential of generating 
1
O2 and other ROS upon UVA irradiation. This theory is supported by 
the fact that accumulating endogenous PPIX by exogenous aminolaevulinic acid (ALA) 
treatment strongly sensitises human skin fibroblasts (FEK4) and keratinocytes (HaCaT) to 
UVA photokilling (Pourzand et al, 1999b).  
The light absorption properties of porphyrins have been used in a type of phototherapy called 
photodynamic therapy (PDT), based on addition of exogenous compounds (e.g. ALA) to 
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increase the level of endogenous photosensitisers (Kennedy et al, 1990; Rittenhouse-Diakun 
et al, 1995; Berg et al, 1996).   
The pigment melanin which is confined to the epidermis and stratum corneum is also 
considered the main chromophore in human skin (Anderson and Parrish, 1981). Melanocytes 
are stimulated upon UVA irradiation and divide and synthesize melanin. Both forms of 
melanin, the reddish (phaeomelanin) and the black (eumelanin), take part in the screening 
effect of the whole epidermis. Reactive species can be generated from UVA irradiation of 
melanin, which may be harmful to the melanocytes and their cellular environment. For 
example human melanoma cells with high melanin content accumulated twice as much 
oxidative DNA damage upon UVA irradiation than cells with low melanin content (Kvam 
and Tyrrell, 1997). There is also evidence from in vitro studies suggesting that another 
important chromophore in the skin, the epidermal urocanic acid (a deamination product of 
histidine) may initiate chemical processes that could lead to the photoaging of the skin 
(Hanson and Simon, 1998). The amino acids tyrosine and tryptophan as well as NADH and 
NADPH, also exhibit absorption within the UVA range (Tyrrell, 1991). 
 
1
O2 and H2O2 are thought to be the most important ROS generated intracellularly by UVA, 
promoting biological damage in exposed tissues via iron-catalysed oxidative reactions (Vile 
and Tyrrell, 1995). It has been shown that physiologically relevant doses of UVA induce lipid 
peroxidation in membranes of human primary fibroblasts and keratinocytes via pathways 
involving iron and 
1
O2 (Vile and Tyrrell, 1995; Morliere et al, 1991; Punnonen et al, 1991). 
Indeed, iron „at‟ or „near‟ strategic targets such as cell membranes, can undergo redox cycling 
by reacting sequentially with one electron reductants and oxidants, thereby generating toxic 
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oxidants such as ·OH and lipid derived alkoxyl and peroxyl radicals and can elicit biological 
damage (Aust et al, 1985; Halliwell and Gutteridge, 1992).  




is not involved in 
any of the cellular effects mediated by UVA observed so far, including lipid peroxidation and 
protein oxidation (Vile and Tyrrell, 1995; Giordani et al., 1997). 
 
Immediate cellular effects of physiologically relevant doses of UVA include depletion of 
cellular glutathione (GSH) content, membrane lipid peroxidation and alteration in nuclear 
transcription factor activity and gene expression (Tyrrell, 1996; Vile and Tyrrell, 1995; 
Djavaheri et al, 1996; Wlaschek et al, 1997; Klotz et al, 1997). The potentiation of UVA 
photokilling by GSH depletion provides further evidence for ROS involvement in UVA 
effects (Tyrrell and Pidoux, 1988).  The UVA-induced generation of 
1
O2 has been shown to 
play a crucial role in UVA-induced peroxidation of membrane lipids of cultured human skin 
fibroblasts as well as activation of nuclear transcription factors such as NF-kappaB (Gaboriau 
et al, 1995; Reelfs et al, 2004). Studies with iron chelators have demonstrated that iron-
catalyzed ROS are also certainly involved in UVA-induced NF-kappaB activation, membrane 
damage and cell death (Reelfs et al, 2004; Zhong et al, 2004; Yiakouvaki et al, 2006; Reelfs 
et al, 2010).  
 
The gene whose expression is most enhanced by UVA, encodes the mammalian stress protein 
and heme degrading enzyme, haem-oxygenase-1 (HO-1) (Keyse, 1989). Because of the 
generality of the response, the transcriptional activation of HO-1 is now used as a marker of 
oxidative stress in mammalian cells (Keyse and Tyrrell, 1989, Tyrrell, 1994). Studies with 
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D2O (that enhances the lifetime of 
1
O2) and sodium azide and L-histidine (two quenchers of 
1
O2) have shown that 
1
O2 may be the primary effector in the transcriptional activation of HO-
1 by UVA in cultured skin fibroblasts (Basu-Modak and Tyrrell, 1993). Further evidence for 
involvement of 
1
O2 in UVA-induced activation of HO-1 is provided by studies showing that 
ALA-mediated increase in endogenous photosensitiser PPIX strongly sensitizes the primary 
human skin fibroblasts to photokilling and drastically lowers the UVA dose threshold for 
activation of the HO-1 gene (i.e. from 50-100 to 5-10 kJ/m
2
) (Pourzand et al, 1999b; Ryter 
and Tyrrell, 1998).  
 
 A major consequence of UVA irradiation of human skin cells is the immediate release of 
chelatable „labile‟ iron in the cytosol that appears to exacerbate the oxidative damage exerted 
by ROS generated by UVA. The UVA-mediated increase in LI in human skin fibroblasts 
plays a key role in activation of NF-kappa B and UVA-induced necrotic cell death (Pourzand 
et al, 1999b; Zhong, 2004; Pourzand and Tyrrell, 1999; Reelfs et al, 2004; Reelfs et al, 
2010).   
 
1.4 Skin defence against UVA 
Stratum corneum, the physical absorption barrier of the skin, protects the epidermal 
keratinocytes and underlying fibroblasts to some extent (Pourzand and Tyrrell, 1999). 
Melanin can act as an additional defence of the epidermis. It provides some degree of 
physical protection and attenuates UV radiation by scattering and dissipation of absorbed 
energy (Tyrrell, 1994, Kollias et al, 1991). Since most cellular components of skin are 
susceptible to potentially deleterious oxidation, the cellular antioxidant systems are crucial to 
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the prevention or removal of the damage caused by the oxidising component of UV radiation. 




1.4.1 Antioxidant Defences 
As mentioned above, skin is the first interface with the external environment. As such it is 
extremely exposed to oxidative stress which generates reactive radical species directly or 
indirectly derived from the presence of oxygen. Due to susceptibility of cellular components 
to potentially harmful oxidation, cell survival could only happen by the existence of a large 
range of antioxidants defences, which are composed of free radical scavengers, either 
enzymatic or non-enzymatic, which sometimes act in synergy. 
In vivo measurements in mouse and human skin have demonstrated that both enzymatic 
(catalase, glutathione peroxidase, glutathione reductase, and heme-oxygenase-2) and non-
enzymatic (GSH, urate, ascorbate) antioxidant capacities of  the epidermis is higher than that 
of the dermis (Shindo et al, 1993; Shindo et al, 1994; Applegate et al, 1995; Applegate et al, 
1996). However UV radiation (UVB and UVA) reduces both enzymatic and non-enzymatic 
antioxidant defences in cultured skin cells (Pourzand and Tyrrell, 1999; Lautier et al, 1992; 
Sies, 1997; and Tyrrell, 1994). Possible mechanisms involved in the defence of the skin 
against UVA-mediated oxidative stress in the skin are presented in this section.  
1.4.1.1. Non-enzymatic molecules 
Glutathione (L-gamma-glutamyl-L-cysteinylglycine, GSH) is an important antioxidant 
molecule that is present in most mammalian cells in high concentrations (i.e. 3-5 mM). One 
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of its most important functions is to protect cells against oxidative damage (Meister and 
Anderson, 1983). 
In human skin cells in culture, there is a direct correlation between the levels of endogenous 
GSH and sensitivity for cell killing by UVA (Tyrrell and Pidoux, 1986; Tyrrell and Pidoux, 
1988). GSH levels modulate the levels of pre-mutagenic damage arising as a result of normal 
metabolism in cultured human cells and following UVA radiation (Applegate et al, 1992). It 
has been shown that in murine skin, GSH in both dermis and epidermis are depleted by UVA 
treatment (Connor and Wheeler, 1987). 
The protection mechanism of GSH is unknown. However, as the most important intracellular 
thiol, it may act directly by scavenging radicals by hydrogen donation, competing with 
protein thiols for oxidising species, or indirectly as a cofactor for a number of protective 
enzymes including glutathione peroxidases (GPxs involved in detoxification of H2O2 or 
organic peroxides) (Ursini et al, 1982; Tyrrell and Pidoux, 1988; Lautier et al, 1992; Jornot 
and Junod, 1993). Many of the radical or non-radical reactions in cells involving GSH may 
lead to thiol oxidation to the disulphide, i.e., the oxidation of GSH to form GSSG. Therefore 
the reaction of reduction of GSH (catalysed by GSSG reductase), as well as the provision of 
essential reducing equivalents (NADPH) to this enzyme, are important in antioxidant 
defense. 
Vitamin E (DL--tocopherol) is thought to be a major lipophilic non-enzymatic, free radical 
scavenger.  Alpha-tocopherol acts as a chain breaking antioxidant in membranes by reacting 
with lipid peroxyl radicals formed during lipid peroxidation.  A number of studies have 
demonstrated that α-tocopherol can inhibit the UVA-mediated lipid membrane damage (e.g. 
Morliere et al, 1991; Gaboriau et al, 1993; Vile et al, 1995; Coulomb et al, 1996; Clement-
Lacroix et al, 1996). In vitro, α-tocopherol is also capable of reacting and quenching 1O2 
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(Grams et al, 1972; Foote et al, 1974), however the importance of this phenomenon in 
biological membranes remains to be established.  
Although the main in vivo function of α-tocopherol is to prevent lipid peroxidation, there is 
still very weak evidence for the photoprotective effects of vitamin E in animal cells and 
tissues (Bissett et al, 1990; Record et al, 1991; Fryer et al, 1993). Some protective effects 
have been reported in rodent cells in culture against UVB-induced cytotoxicity (Sugiyama et 
al, 1992), but not against DNA damage. Topical application of α-tocopherol acetate on the 
skin of mice prevented UVB-induced erythema and sunburn (Trevithick et al, 1992). UVA-
induced cytotoxicity could be inhibited only in the case of a photosensitivity disease i.e. solar 
dermatitis (sun burn) by a water soluble vitamin E analogue, Trolox C, (Kralli and Moss, 
1987). Nevertheless, in Pourzand‟s laboratory, it has been demonstrated that pre-treatment of 
cultured human primary fibroblasts with α-tocopherol-acetate could partially protect the cells 
against UVA-induced lysosomal damage and necrotic cell death (Julia Li Zhong, PhD thesis, 
2002). Finally, there is evidence that vitamin E, at least when applied topically to the skin, is 
able to protect partially against ozone-mediated lipid peroxidation (Thiele et al, 1997). 
 
Alpha-tocopherol is closely coupled to both vitamin C (ascorbate) and thiol cycle for the 
generation and maintenance of sufficient levels of cellular reducing power. The hydrophilic 
antioxidant, vitamin C (ascorbate) has a reducing ability (Berger et al, 1997). Furthermore, 
vitamin C may have a role in preventing oxidative damage by acting synergistically with 
vitamin E. The GSH-dependent free radical reductase may also generate oxidised vitamin E. 
A dietary antioxidant mixture (vitamin E, vitamin C and GSH) clearly reduced the UVB-
induced tumour multiplicity and increased the tumour latent period in mouse studies (Black 
et al, 1985), demonstrating the importance of the concept of interaction between different 
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antioxidants. Ascorbate is able to react with a variety of active oxygen species (Halliwell and 
Gutteridge, 1989). It is, for example, able to quench 
1
O2 (Chou and Khan, 1983), which is 
potentially an important way of protection in biological systems where 
1
O2 is produced in the 
aqueous phase. However, ascorbate may also act as a pro-oxidant, since it can efficiently 
reduce iron Fe(III) to Fe(II), making it available for Fenton-type reactions. For example, 
ascorbate stimulates iron-dependent peroxidation of membrane lipids in certain 
circumstances (Muakkassah-Kelly et al, 1982; Basu-Modak et al, 1996). 
Carotenoid pigments, such as vitamin A (β-carotene), are lipid-soluble compounds which can 
protect cells against photosensitised reactions in a few different ways (Krinsky and Deneke, 
1982), including quenching of triplet sensitisers, quenching (inactivation) of 
1
O2. This 
property is particularly important in the skin, since 
1
O2 is probably the primary species 
generated by the interaction of UV/visible radiation with the photosensitizer PPIX present 
close to the skin surface. Beta-carotene has been proven to inhibit UV-induced epidermal 
damage and tumor formation in mouse models (Epstein, 1977; Mathews-Roth and Krinsky, 
1987). 
The role of the antioxidant in protecting cells against UV-induced oxidative stress requires 
further clarification. Since the long wavelengths in sunlight can penetrate through tissue and 
into blood, these defences may be critical under certain circumstances. 
 
1.4.1.2 Enzymes and Molecules 
The enzymatic system of the skin acts by catalysing the decomposition of oxidants and free 
radicals into less reactive species. Mammalian detoxifying enzymes include catalase, 
glutathione peroxidases/reductases, thioredoxin reductase and SOD. The haemoprotein 
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catalase specifically destroys H2O2 and is found in peroxisomes. Glutathione peroxidases 
(GPxs) and associated enzymes form a family of selenium-dependent haemoproteins which 
not only detoxify H2O2 but also reduce harmful hydroperoxides, such as those resulting from 
lipid peroxidation (Ursini et al, 1995). Peroxidases are found in the cytoplasm, peroxisomes 
and in the mitochondria. Superoxide dismutases (SODs), i.e. Cu, Zn-SOD, Mn-SOD and EC-
SOD convert ·O2
-
 to H2O2 and are found respectively in the cytoplasm, mitochondria and 
bound to the extracellular matrix. 
In cultured human cells, GPx and SOD are not affected by UVA radiation; however catalase 
is very sensitive to UVA and could be inactivated as a result of the radiation insult (Moysan 
et al, 1993; Tyrrell and Pidoux, 1989). 
Enhancing GPx activity of cultured human cells by supplementing them with selenium 
provided protection against UVA-mediated damage (Leccia et al, 1993). Conversely, 
selenium deprivation of cells sensitized them to UVA and H2O2
-
mediated cytotoxicity and 
lipid peroxidation (Bertling et al, 1996).  
The thioredoxin/thioredoxin reductase (Trx/TR) system may also have a role in the cellular 
defence of skin against oxidative stress including that induced by UV radiation. Thioredoxin 
is a small protein which, in its reduced form, has a general protein disulfide reductase activity 
via its two reactive thiol groups (Holmgren et al, 1985). Thioredoxin reduces free radicals in 
human keratinocytes in vivo (Schallreuter et al, 1986). Thioredoxin expression is induced by 
oxidative stress, including H2O2 and UV (Spector et al, 1988; Nakamura et al, 1994) in a 
variety of cell types in culture including keratinocytes. The result is an increased protective 
capacity of the cell. A prognostic value for Trx has been described in malignant melanoma 
(Schallreuter et al, 1991). 
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Since iron has an important role as a catalyst in oxidative reactions, iron transport- and 
storage- proteins may play an important part as constitutive and/or inducible antioxidant 
defense, by keeping ”circulating iron” low and in a non-toxic form. The intracellular storage 
protein Ft appears to play a critical role in this respect (see section 1.5). 
Similarly, owing to its metal binding capacity, metallothionein (MT) could contribute to skin 
protection against phototoxicity injury. In fact, metallothionein (MT) has been shown to be 
induced in vitro by UVC and UVB radiation (Stein et al, 1989; Hansen et al, 1997). Rodent 
cells with elevated levels of metallothionein have been shown to have increased resistance to 
UVA radiation (Dudek et al, 1993). The induction of expression of this gene also seems to 
correlate with a resistance to killing by several mutagenic agents. However, basal MT level 
may also function to regulate intracellular redox status in mammalian cells, since rodent MT 
null cells showed enhanced sensitivity to oxidative stress (i.e. tert-butylhydroperoxide) as 
compared to normal cells (Lazo et al, 1995). 
Finally the copper-containing protein caeruloplasmin (both plasma and cytoplasmic forms) 





 (ferroxidase activity), thus preventing the iron from entering into a reversible redox 
system (Omoto and Tavassoli, 1990). This may facilitate iron incorporation by iron-binding 
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 1.5. Iron  
1.5.1 Body Iron 
Iron is the second most abundant metal, after aluminium and the fourth most abundant 
element in the earth‟s crust (5%) (Halliwell and Gutteridge, 1989). Living organisms, from 
bacteria to mammals, have selected iron to help them through vital biological processes, in 
which it is involved as part of, or as cofactor of proteins and enzymes (Aisen and Listowsky, 
1980). Iron is a critically important metal for a wide variety of cellular events due to its 
important role in the active sites of a wide range of proteins involved in energy metabolism, 
respiration and DNA synthesis (Le and Richardson, 2002). 
The total amount of iron in an average human body is about 4-5 g (Trenam et al, 1992), the 
majority of which is incorporated into the haem complex and can be found in proteins such as 
haemoglobin, myoglobin and cytochromes. The other type of iron is in the form of non-haem 
iron which is found in iron-sulfur cluster proteins such as IRPs as well as in iron transport 
protein transferrin (Tf), and iron storage protein Ft and hemosiderin (Cairo, 2006).   
Iron is absorbed from the mammalian gastrointestinal tract by two protein-mediated 
mechanisms, one absorbing iron (II) and the other iron as haem (Shayeghi et al, 2005). 
Primates have evolved not to be able to excrete iron and, therefore, body iron levels are 
totally controlled by the absorption process (Andrews, 1999). The control of body iron is very 
important, because iron could be toxic when accumulated in excess. In the presence of 
molecular oxygen, „loosely-bound‟ iron is able to redox cycle between the two most stable 
oxidation states, iron (II) and iron (III), thereby generating oxygen-derived free radicals such 
as ·OH.  The pathological consequence of iron-catalyzed oxidative damage are recognized in 
diseases such as hepatitis, haemochromatosis, liver cirrhosis, cancer and neurodegenerative 
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disease (Andrews, 1995; Gaeta and Hider, 2005; Kalinowski and Richardson, 2005; Molina-
Holgado et al, 2007; Bacon and Britton, 1990; Kehrer, 2000; Kowdley, 2004; Valko et al, 
2006; Valko et al, 2007). Excess iron may also aggravate diabetes, cancer, cardiovascular 
disease and alcoholic and non-alcoholic steatohepatitis (Swanson, 2003; Brewer, 2007; 
Kongho et al, 2005; Peterson, 2005; Imeryuz et al, 2007).  The presence of excess iron has 
also been demonstrated in a variety of skin disorders such as psoriasis (Molin and Wester, 
1973), venous ulceration (Ackerman et al, 1988) and atopic eczema (David et al, 1990), 
indicating the involvement of iron in the pathology of skin. Iron may also play a role in the 
carcinogenic process of other transition metals such as copper, or other types of carcinogens 
(Toyokuni et al, 1996). 
 
About 60% of the total body iron is incorporated in haem of haemoglobin in the circulating 
red blood cells for oxygen transport and 15% in the muscles in the form of myoglobin 
(Crichton et al, 2008). Only a very small amount of the total body iron is present in 
functional iron, as an essential component of a very large number of heme (e.g. cytochromes, 
catalase, oxidases and peroxidases) and non-haem proteins and enzymes (e.g. ribonucleotide 
reductase, oxidases and iron sulfur-proteins). Most of these proteins are required for normal 
cellular metabolism and are involved in important processes such as oxidative production of 
cellular energy, electron transfer and DNA biosynthesis. All of these may account for no 
more than 10% of the total iron pool. The remaining 15% can be found principally in the 
cytoplasm in the form of the iron-storage protein Ft but also in lysosomes, as hemosiderin. 
Storage iron is found in the liver, mainly in the hepatocytes, but it is also found in 
macrophages in the liver, bone marrow, spleen and muscles, where it is readily available as a 
reserve in case of blood loss (Kuhn, 1994; Crichton et al, 2008).  
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All these iron-complexing molecules leave body fluids and cells with extremely low 
concentration of free transit iron. Nevertheless there is now strong evidence for the existence 
of a transit pool of catalytically active free iron known as labile iron pool.  
Indeed in contrast to iron bound to proteins, the intracellular labile iron can be potentially 
toxic, especially in the presence of ROS, as it can lead to catalytic conversion of „poorly 
reactive‟ oxygen species into „highly reactive‟ and damaging oxygen-derived free radicals 
such as ·OH radical and lipid-derived alkoxyl and peroxyl radicals (Halliwell and Gutteridge, 
1990; Halliwell and Gutteridge, 1992). The highly reactive ·OH radical species are capable of 
interacting with most types of biological material including sugars, lipids, proteins and 
nucleic acids. These interactions that promote various injurious processes in cells such as 
lipid peroxidation, protein oxidation, DNA/RNA oxidation and DNA lesions, ultimately 
overwhelm the cellular antioxidant defense mechanisms and lead to cell damage and cell 
death.  
 
1.5.2. Labile iron pool (LIP) 
The cellular LIP is defined as a pool of redox-active iron complexes and it was first suggested 
by Jacobs (1977) as an intermediate or transitory pool between extracellular iron and cellular 
iron associated with proteins. Iron belonging to this intracellular pool comprises both ionic 




) loosely bound to low molecular weight ligands such as organic 
anions (phosphates and carboxylates), polypeptides and surface components of membranes 
(e.g. phospholipid head groups) (Kakhlon and Cabantchik, 2002; Kruszewski, 2003). Labile 
iron pool is accessible to permeant chelators and is considered metabolically and catalytically 
reactive (Breuer et al, 1996; Epstein et al, 1997; Cairo and Pietrangelo, 2000; Petrat et al, 
2001). This definition implies that LIP can not only potentially participate in redox cycling 
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but also be scavenged by permeant chelators. The latter property forms the basis for the 
quantification of the cellular LIP, which in quiescent conditions comprises only minor 
fractions of the total cellular iron (< 5%) (Kakhlon and Cabantchik, 2002). Originally, LI was 
considered to be cytosolic, however recent studies have indicated that only a minor fraction 
of the total cellular redox-active iron resides in the cytosol. The quantitative studies of LIP in 
various cell lines using a series of fluorescent iron probes have shown that lysosomal 
compartments have the highest proportion of LI followed by mitochondria that have much 
superior level of LI when compared to cytosolic pool (Petrat et al, 2000; Petrat et al, 2000,    
2001; Fakih et al, 2008).   
 
 
1.5.3. Cellular iron homeostasis 
The level of LIP within cells must be maintained so that there is adequate iron for the cell‟s 
requirement but not so much that it becomes toxic. Alterations in LIP are normally sensed by 
the cytosolic iron IRP1 and IRP2 which function as post-transcriptional regulators of both 
iron uptake via the TfR and iron sequestration by the iron storage protein, Ft (see Figure 8 
and 9): 
When iron is scarce in the LIP, Ft and TfR mRNAs are specifically recognized and bound by 
the active forms of IRPs (IRP1/2), leading to stabilization of the TfR mRNA and inhibition of 
Ft translation, both of which will lead to enhanced levels of LIP. 
Conversely, during an increase in iron supply, IRPs are converted to low affinity mRNA-
binding proteins, leading to the induction of Ft mRNA translation and the degradation of TfR 
mRNA, which will ultimately lead to a reduction in the LIP (Klausner et al, 1993; Beinert 
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and Kennedy, 1993; Kuhn, 1994; Guo et al, 1995; Pantopoulos, 2004; Hentze and Kuhn, 
1996).  
 
Figure 8. The reciprocal translational regulation of transferrin receptor (TfR) and ferritin (Ft) by IREs 
and IRPs. (Modified from Yiakouvaki, 2003 PhD thesis). 
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Figure 9. The schematic presentation of regulation of Ft mRNA translation by IRP-1 during 
high and low intracellular labile iron conditions. (Reproduced from C. Pourzand‟s presentation 
slide, with permission) (Pourzand et al, 1991a). 
 
1.5.4. Cellular iron uptake 
Within the body the supply of iron to tissues and cells is mediated by two principal proteins, 
namely transferrin and TfR.  
Transferrin (Tf) is the plasma iron-binding glycoprotein which is considered as the main 
source of iron transfer in the body. It is responsible for iron supply for biological needs of 
iron requiring cells and is considered the only available source of iron for haemoglobin 
synthesis (Cairo et al, 2006). Its function is to reduce the toxicity of iron by binding and 
transporting iron. The 80kDa Tf has high affinity for Fe
3+
, and it consists of two globular 
domains, each of which can independently bind a single ferric ion. In conditions of normal 
iron status, serum Tf is saturated to about one third of its iron-binding capacity, such that a 
mixture of apo-Tf (iron free), the two monomeric forms (one iron) and diferric-Tf (two iron) 
is present.   
- 39 - 
 
The 180kDa TfR is a glycoprotein which mediates the entry of diferric-Tf from the 
extracellular compartment into the cells (Eisenstein and Blemings, 1998). This glyoprotein is 
a disulfide-linked homodimer composed of two identical glycosylated subunits. The subunits 
are transmembrane polypeptides of 760 amino-acid residues with a short N-terminal 
cytoplasmic domain, a single transmembrane region and a large glycosylated portion, which 
contains the Tf-binding site. Up-regulation of the expression of cellular TfR occurs as a result 
of an inadequate tissue supply of iron or increased cellular demand for iron. As a result, 
elevation of soluble form of TfR can be found in the context of iron deficiency diseases. 
There are two forms of TfR, named TfR1 and TfR2 which are thought to have distinct cell 
and tissue specific expression pattern. (Kawabata et al, 1999; Levy et al, 1999). TfR is 
expressed at high levels in rapidly dividing cells (Kalinowki and Richardson, 2005).  
Although, in normal subjects, Tf is made up of different proportions of the four Tf species 
described above, it is predominantly the diferric-Tf (Fe2-Tf) molecule that is utilised by the 
cell.  
Figure 10 summarises the mechanism by which cells uptake iron from Tf via TfR (Andrews, 
1999). Briefly the Fe2-Tf molecule binds to the TfR at the plasma membrane. The transferrin-
transferrin receptor (Fe2-Tf-TfR) complex are localised in clathrin-coated pits, which pinch 
off from the membrane, and after losing their clathrin coats, they fuse with the target 
membranes of endosomes delivering the vesicle contents into the interior of the endosome. 
An ATP-dependent proton pump maintains the pH of the endosome at around 5-6. This 
intracellular compartment functions as a sorting station in the inward pathways of 
extracellular molecules into the cell, known as receptor-mediated endocytosis. The early 
endosomes containing Fe2-Tf-TfR, are rapidly sorted, enabling them to escape from 
subsequent lysosomal degradation. Conformational changes of the Fe2-Tf-TfR complex at 
mildly acidic pH within the endosome lead to release of iron from the complex as Fe
3+
. The 
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apoTf-TfR complex is returned to the cell surface, where the complex dissociates, allowing 
both components to be reutilised in further cycles of cellular uptake of Tf iron. The 
endosomal Fe
3+
 which has been released from the Fe2-Tf-TfR complex must be reduced to 
Fe
2+
 before the divalent metal ion transporter (DMT1) can transport it across the endosomal 
membrane into the cytoplasm. The identity of the ferrireductase involved in this process 
remains unknown. Once in the cytoplasm, the Fe
2+ 
enters the intracellular transit iron pool, 
referred to as LIP. In erythroid cells most of this iron enters the mitochondria, where it is 
incorporated into heme, whereas in non-erythroid cells, iron from the LIP can be stored in Ft.         
 
 
Figure 10. Cellular iron uptake. (modified after Andrews 1999). Iron bound to Tf is internalised 
into cells by TfR-mediated endocytosis. Iron is then released from Tf-TfR complex in endosomes and 
is transported across the endosomal membrane by DMT1 which is present in endosomal membrane. 
Once in cytosol iron enters the intracellular LIP and can be either stored in Ft (i.e. in non-erythroid 
cells) or enter mitochondria for heme synthesis (i.e. in erythroid cells).     
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1.5.5. Cellular iron storage 
Within the cell, iron can be stored in two forms, in the cytosol as Ft and after breakdown of 
Ft within the lysosomes, as heamosiderin. Ft is an oligomeric protein which forms a hollow 
protein shell within which substantial amounts of iron can be stored in a non-toxic, soluble 
and bioavailable form. In contrast, heamosiderin is water-insoluble, contains a much higher 
ratio of iron to protein and can be directly visualised histologically by its characteristic 
Prussian blue reaction (i.e. the Perl‟s stain) (Crichton et al, 2008).  
Most of the iron that is not metabolised is stored in the cytosolic iron storage protein, Ft. Ft is 
an ubiquitously expressed hollow protein which is made up of 24 polypeptide subunits. The 
heteropolymeric components (light chain, L, 19 kDa; and heavy chain, H, 21 kDa) form a 
shell around an inorganic iron oxyhydroxide core [FeOOH]x. The sequestered iron is 
maintained in an oxidised Fe
3+
 state by the ferritin H-chain, which has ferroxidase activity. 
This form of storage is thought to protect iron from reduction (Balla et al, 1992). The L-chain 
has more iron storage capacity and facilitates iron core formation within the protein shell. 
The proportion of L and H chain depends on the tissue source as well as the level of iron 
loading. The mammalian H-Ft and L-Ft polypeptides show 50% homology and have the same 
ancestral gene (Ponka et al, 1998). 
One Ft molecule could accommodate up to 4500 iron atoms as a crystalline core of ferric ions 
(Richter, 1978). Normally, Ft is only about 20% iron saturated (Reif, 1992) and as much as 
one third of Ft iron may turn over daily as a result of degradation and synthesis. Ft is slowly 
degraded to a non specific complex containing iron, which becomes a component of 
hemosiderin. Hemosiderin is a lipoprotein found in lysosomes, which happens to be a dead 
end in the metabolism of iron and Ft (Koorts and Viljoen, 2007). Ft has a high capacity to 
chelate iron by converting it to ferric state which is a safer form. As a result Ft is able to 




 availability to take part in Fenton reaction. Chelation of intracellular iron by 
storage in Ft, when the level of endogenous LI increases protects mammalian cells in culture 
against oxidative stress generated by a variety of factors (Balla et al, 1992; Vile et al, 1993 
and 1994). 
Despite Ft‟s iron scavenging property, it may also be a hazardous molecule, if exposed to 
pathological conditions leading to oxidative stress (see below). 
 
1.5.6. Iron homeostasis and oxidative stress 
Under pathological conditions, including oxidative stress, iron homeostasis is severely altered 
(Cairo and Pietrangelo, 2000; Deb et al, 2009).  Disregulation of iron homeostasis leads an 
increase in intracellular LI, which may have harmful consequences on cells.  
Iron bound to low molecular weight ligands constitutes a potential source of catalytic iron 
upon UVA radiation. In vitro, physiological doses of UVA radiation may reduce ferric iron 
bound to the potential low molecular weight intracellular chelator citrate (Vile and Tyrrell 
1995).  
Different conditions of stress such as UVA radiation (Aubailly et al, 1991), ·O2
-
(Biemond et 
al, 1988) and reducing agents (Baader et al, 1994) have been shown in vitro to induce 
reductive release of iron from Ft.  
Ft plays a dual role in LIP homeostasis. In one hand it acts as an iron-sequestering protein 
and in another hand act as a potential source of LIP. The cytoprotective role of Ft remained 
largely hypothetical until it was shown that cells overexpressing this protein are more 
resistant to oxidative injury (Balla et al, 1992; Cermak et al, 1993; Lin and Girotti, 1997). 
Overexpression of the H-subunit of Ft also decreased the LIP level (Picard et al, 1998) and 
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the H2O2-induced DNA damage (Cozzi et al, 2000). Conditional deletion of H-Ft in mice 
induced loss of iron storage and liver damage (Darshan et al, 2009). At cellular level, the 
deletion of H-Ft in mouse embryonic fibroblasts increased the intracellular LIP and probably 
as a direct consequence, ROS increased rapidly within the cells even at low extracellular iron 
concentrations (Darshan et al, 2009). Downregulation of H-Ft has also been shown to occur 
in murine and rat models of heart failure, leading to increase in LIP, oxidative stress and cell 
death (Omiya et al, 2009).  
Various reductants and chelators, including physiological and toxicological substances, can 
also release iron from Ft (Koorts and Vilijoen, 2007). Effective reducing agents for the 
release of iron from Ft include flavins, cysteine, GSH, ascorbic acid and ·O2
-
(Ponka et al, 
1998).  
Iron is also liberated from Ft as a consequence of normal turnover in lysosomal 
compartments, where it is recycled for heme synthesis (Vaisman et al, 1997; Radisky and 
Kaplan, 1998). This source of LIP has been shown to be active in the cell-damaging 
processes caused by oxidative stress promoting lysosomal rupture and release of potent 
hydrolytic enzymes to the cytosol (Ollinger and Brunk, 1995; Brunk et al, 1995, Roberg and 
Ollinger, 1998, Pourzand et al, 1999a). 
It has been shown that during oxidative stress, iron could also be released from Ft as a result 
of its proteolyic degradation (Roberg and Ollinger, 1998, Pourzand et al, 1999a). For 
example studies from this laboratory have revealed that exposure of human skin fibroblasts to 
physiologically relevant doses of UVA, leads to immediate and dose-dependent increases in 
potentially harmful LI in skin cells that plays a key role in the increased susceptibility of skin 
cells to UVA-mediated oxidative membrane damage and necrotic cell death and almost 
certainly act to exacerbate damage caused by further exposure (Pourzand et al, 1999a; Zhong 
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et al, 2004; Reelfs et al, 2004). Further investigation in this field has revealed that UVA 
promotes immediate damage to both lysosomal and mitochondrial membranes. The 
lysosomal damage leads to leakage of potentially harmful lysosomal proteases into the 
cytosol which in turn attacks cytosolic proteins, notably the cytosolic iron storage protein, Ft. 
The proteolytic degradation of Ft contributes to an increase in cytosolic LIP (see Figure 11).  
 
                          
Figure 11. The UVA-induced damage to lysosomes. Exposure of skin fibroblasts to UVA promotes 
immediate (i.e. 0h) damage to lysosomal membrane leading to leakage lysosomal proteases into the 
cytosol. Once in cytosol, the lysosomal proteases degrade Ft and release its iron in the form of LI 
(Fe
2+
) (Pourzand et al, 1999a).  
 
The lack of cytosolic iron storage protein, Ft within the first hours after irradiation further 
exacerbate the iron-catalyzed damage in irradiated skin cells, since potentially harmful excess 
amounts of LI can not be safely sequestered. Indeed increase in intracellular LI along with 
ROS generated by UVA radiation promotes further peroxidative damage in exposed skin 
cells notably in plasma membrane that results in loss of cell membrane integrity. This 
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coincides with concomitant UVA-mediated damage to mitochondrial membrane that in turn 
leads to abrupt interruption of electron chain reactions within the mitochondrial membrane 
and production of ROS as well as depletion of mitochondrial ATP, all of which lead to 




Figure 12. Pathways of UVA-induced necrotic cell death in skin fibroblasts. Exposure of skin 
fibroblasts to UVA promotes immediate (i.e. 0h) release of labile iron (Fe
2+
) that exacerbate the 
peroxidative damage in plasma and mitochondrial membranes leading to loss of intracellular ATP and 
loss of membrane integrity, both of which cause necrotic cell death. Pretreatment of cells with strong 
iron chelators such as desferal (DFO) or membrane antioxidants (e.g selenium; se, butyryl 
hydroxytoluene ; BHT or α-tocopherol) could protect the cells against UVA-induced membrane 
damage and ncecrosis. Restoring the intracellular ATP with glucose could protect the cells from 
necrosis (Pourzand et al, 1999a; Zhong et al, 2004; Reelfs et al, 2010).  
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The potential role of Ft iron in exacerbating UVA-induced damage was further strengthened 
by studies showing that increasing Ft synthesis in cells by iron loading in the form of iron 
citrate or hemin, could lead to substantial increase in UVA-induced LI release and necrotic 
cell death (Zhong et al, 2004; Reelfs et al, 2004; Reelfs et al, 2010). Conversely conditional 
deletion of H-Ft in an oxidant-sensitive strain of mouse embryo fibroblasts (Darshan et al, 
2009) caused a decrease in UVA-induced iron release and cell damage (unpublished data, 
Pourzand‟s laboratory- personal communication)      
Oxidative stress can also affect iron homeostasis via activation of the haem-catabolising 
enzyme HO-1 as exemplified in UVA-irradiated skin fibroblasts cells. Studies from Tyrrell‟s 
laboratory have shown that UVA promotes haem release from microsomal haemoproteins 
immediately after UVA irradiation of FEK4 cells (Kvam et al, 1999). Although haem itself is 
not a source of LIP, it is a substrate for HO-1 and HO-2, both of which could release the 
haem iron and as such contribute to the increase in potentially harmful LIP observed after 
UVA irradiation. Indeed Kvam et al (2000) have shown that HO-activity can cause 
hypersensitivity to oxidative UVA radiation due to release of iron from haem. The UVA-
mediated transcriptional activation of HO-1 gene eventually (i.e. 1-2 days) leads to HO-1-
dependent increase in Ft (Vile and Tyrrell, 1993) and a consequent lowering of the pro-
oxidant state in skin cells (Vile et al, 1994).  
 
Iron regulatory protein-1 (IRP1), which may itself act as potentially important iron/citrate 
carrier, is susceptible to oxidative inactivation of RNA binding in vitro and in vivo (Hentze et 
al, 1989; Mullner et al, 1992; Cairo et al, 1996). Down-regulation of IRP1 occurs also in vivo 
in liver tissue of the rats subjected to ischemia reperfusion or phorone, a GSH-depleting agent 
(Cairo et al, 1995; Tacchini et al, 1997). Exposure of skin cells to UVA also inactivates IRP1 
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binding activity (Pourzand et al, 1999b). By contrast, menadione, nitric oxide, and H2O2 
(Martins et al, 1995; Pantopoulos and Hentze, 1995) activate IRP1 RNA binding activity and, 
as a result, lead to a coordinated decrease of Ft synthesis and induction of TfR expression. 
Nevertheless exposure to H2O2 has been shown to induce LI release, although its underlying 
mechanism is under debate (Breuer et al, 1997; Yiakouvaki et al, 2006).  
 
1.6. Photodynamic therapy (PDT) 
1.6.1. Definition  
The combination of photosensitising chemicals and light to treat skin diseases has been 
widely practiced in dermatology for centuries. This practice dates back to ancient Egypt, 
India and Greece, where psoralen-containing plants extracts and light were applied to treat 
psoriasis, vitiligo and skin cancer (Wilson and Mang, 1995).  This concept, generally known 
as photochemotherapy, represents a common basis for different treatment procedures such as 
PUVA (i.e. psoralen-UVA) and photodynamic therapy (PDT).  
Photochemotherapy is a form of phototherapy in which a chemical substance is used in 
addition to light. In PDT, O2, light and a photosensitising drug are used in combination (see 
Figure 13). The first component of PDT is the „photosensitiser‟ – a photosensitive molecule 
that localizes to a target cell and/or tissue. The second component involves the administration 
of light of a specific wavelength that activates the photosensitiser. The photosensitiser 
transfers energy from light to molecular oxygen, to generate ROS (Ryter and Tyrrell, 1998).  
These reactions occur in the immediate locality of the light-absorbing photosensitiser. 
Therefore the biological responses to the photosensitiser are activated only in the particular 
areas of tissue that have been exposed to light. 
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Figure 13. Mechanism of action of photodynamic therapy (PDT). PDT requires three elements: 
light, a photosensitiser and oxygen. When the photosensitiser is exposed to specific wavelengths of 
light, it becomes activated from a ground to an excited state. As it returns to the ground state, it 
releases energy, which is transferred to oxygen to generate ROS, such as singlet oxygen (
1
O2) and free 
radicals. The generated ROS mediate cellular toxicity. 
 
1.6.2. Cell/tissue damage mechanisms of PDT 
PDT is a selective treatment modality that affects mainly the target tissue. The selectivity is 
based on a difference in the photosensitiser concentration between normal and target tissues 
and on the directing light into the target tissue. One advantage of PDT is that the 
photosensitiser can be administered orally, intravenously or by topical application to the skin. 
However these affect its biodistribution (Dolmans et al, 2003). Because biodistribution 
changes over time, the timing of light exposure is another way to regulate the effects of PDT. 
After administration, the photosensitiser accumulates in the target tissue during 3-96 h, 
depending on the photosensitiser used. After this accumulation period, light directed to the 
tissue activates the photosensitiser and, in the presence of ground-state (triplet) oxygen (
3
O2), 
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ROS are formed.  Briefly, following the absorption of light (photons), the sensitiser is 
transformed from its ground state (single state) into a relatively long-lived electronically 
excited state (triplet state) via a short-lived excited singlet state (Henderson and Dougherty, 
1992). The excited triplet can undergo two kinds of reactions (see Figure 14).  First it can 
react directly with a substrate such as the cell membrane or a molecule and transfer hydrogen 
atom (electron) to form radicals. These radicals in turn can transfer their excessive energy to 
ground state oxygen (
3
O2) to form 
1
O2 and other oxygenated reactive species (type I 
reaction). Alternatively, the triplet can transfer its energy directly to ground state oxygen, to 
form 
1
O2 (type II reaction).  
Both type I and type II reactions occur simultaneously and the ratio between these processes 
depends on the type of photosensitiser used, the concentrations of substrate and oxygen, as 
well as the binding activity of the photosensitiser for the substrate. Because of the high 
reactivity and short half-life of the ROS, only cells/ cellular components that are proximal to 
the area of the ROS production (i.e. areas of photosensitiser localisation) are directly affected 
by PDT (Moan and Berg, 1991). Among generated ROS, 
1
O2 is regarded as the main 
mediator of phototoxicity in PDT as it is a powerful oxidant that can react with many kinds of 
biomolecules. These include unsaturated triacyl glycerols, cholesterol, phospholipids, amino 
acids such as tryptophan, histidine and methionine as well as nucleic acid bases such as 
guanine and guanosine (Milgrom and MacRobert, 1998; Stemberg et al, 1998). The 
generated ROS then damage vital structures and functions of cells, which result in tissue 
destruction (Bonnet, 1999; Milgrom and MacRoberts, 1998; Nyman and Hynninen, 2004). 
Eventually, however, the photosensitiser is degraded by light. This process, known as 
„photobleaching‟ can results from reactions of type I or type II (see also section 1.3.1.3 and 
1.3.2). Photosensitized, O2-dependent reactions in biological systems are known as 
photodynamic action (Spikes, 1997). 
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Figure 14. Type I and Type II reactions in PDT. Following the absorption of light, the sensitiser is 
transformed from its ground state into an excited state. The activated sensitiser can undergo two kinds 
of reaction. First it can react directly either with the substrate such as the cell membrane or a 
molecule, transferring a hydrogen atom to form radicals. The radicals interact with oxygen to produce 
oxygenated product (
1
O2) (type I reaction). Alternatively the activated sensitiser can transfer its 
energy directly to oxygen to form 
1
O2 (type II reactions). These species oxidize various substrates and 
damage vital structures and functions of cells.  
 
The extent of photodamage and cytotoxicity is multifactorial and depends on the type of 
photosensitiser, its extracellular and intracellular localization, the total dose administered, the 
total light exposure dose, light fluence rate, oxygen availability and the time between the 
administration of the drug and light exposure. All of these factors are interdependent. 
(Palumbo, 2007; Dolmans et al, 2003; Nowis et al, 2005).   
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It is generally acknowledged that PDT achieves tumour damage by three interdependent 
processes (i) direct tumour cell killing; (ii) damage to the vasculature and (iii) activation of 
non specific immune response (Golab et al, 2000; van Duijnhoven et al, 2003; Abels, 2004). 
Direct cell killing is the most important effect seen after photoactivation that appears to also 
be photosensitiser-dependent (Henderson et al, 1985). Cell death is brought about by the 
local formation of ROS. However both the non-homogenous distribution of oxygen within 
the tumour that may lead to non-homogenous activation of the photosensitiser and the 
asymmetrical distribution of the photosensitiser within the tumour mass and surrounding 
tissue could result in incomplete therapeutic response (Korbelik and krosl, 1996). Oxygen 
shortage can arise as a result of the photochemical consumption of oxygen during the 
photodynamic process as well as from the immediate effects of PDT on the tissue 
vasculature. Indeed rapid and substantial reduction in the tissue oxygen tension during and 
after illumination of photosensitised tissue has been reported (Tromberg et al, 1990; Pogue et 
al, 2001). Although the development of microvascular damage and hypoxia after PDT has 
been shown to contribute to the long-term tumour response, the reduction in oxygen that 
occurs during PDT can limit the response. There are two ways to overcome this problem. 
One is to lower light fluence rate to reduce oxygen consumption rate and the other is to 
fractionate the PDT light delivery to allow re-oxygenation of the tissue (Messman et al, 1995; 
Pogue and Hasan, 1997; Curnow et al 2000). 
 
Cell death in PDT may occur by apoptosis or necrosis, depending on the sensitiser, PDT 
drug-light dose and on the cell genotype (Almeida et al, 2004). Apoptosis is a tightly 
controlled, energy-consuming process of suicidal cell death involving activation of hydrolytic 
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enzymes such as proteases and nucleases leading to DNA fragmentation and degradation of 
intracellular structures (Reed, 2000). Necrosis is the pathological process, which occurs when 
cells are exposed to a serious of physical or chemical insult whereas apoptosis or 
programmed cell death is the physiological process responsible for the elimination of 
superfluous, aged or damaged cells.  
 
Although apoptosis is necessary for both health and disease, necrosis is always the outcome 
of severe and acute injury. Apoptosis and necrosis have long been considered as two distinct 
mechanisms of cell death, each with different biochemical and morphological characteristics 
(Wyllie et al, 1980; Majno and Jorris, 1995). Apoptotic cells are defined by fragmented 
nuclei with condensed chromatin, fragmented or condensed cytoplasm and formation of 
apoptotic bodies, whereas necrotic cells are characterized by electron-lucent cytoplasm, 
mitochondrial swelling and loss of plasma integrity without severe nuclear damage (see 
Figure 15). 
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Figure 15. A comparison of different morphological features of apoptosis versus 
necrosis. In apoptotic cell death plasma membrane is intact until late stage; however 
cytoplasm shrinks and nucleus condenses in early stage of apoptosis. Cells then fragment into 
smaller bodies called apoptotic bodies followed by lysis in a process called „secondary 
necrosis‟. In necrotic cell death, early loss of membrane integrity leads to swelling of 
cytoplasm and mitochondria. This in turn leads to cell membrane breakdown and 
disintegration of organelles (i.e. complete lysis).Adapted from „Apoptosis and cell 
proliferation‟, second edition, Roche. 
 
It has been shown that both necrosis and apoptosis are rapid and dominant form of cell death 
following PDT in multiple experimental settings utilizing various photosensitisers and cell 
types (Oleinick et al, 2002). Indeed, increasing amount of experimental data indicate that at 
optimal PDT conditions (i.e. sufficient photosensitiser concentration and light exposure) 
tumour cells die by necrosis (Nowis et al, 2005). Factors that promote necrosis may include 
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extra-mitochondrial localization of photosensitiser, high dose PDT and glucose starvation 
(Almeida et al, 2004; Dellinger, 1996; Kiesslich et al, 2005; Oberdanner et al, 2002; 
Kirveliene et al, 2003; Plaetzer et al, 2002), although the research in this field is still ongoing.  
 
Apoptotic cell death in PDT is mostly observed with photosensitisers that accumulate in 
mitochondria (Krieg et al, 2003; Fabris et al, 2001). However increasing the photosensitiser 
concentration and light dose usually switches the apoptotic cell death to necrosis. The latter 
appears to be related to the availability of intracellular ATP following PDT. Indeed it is now 
well established that the progression to necrotic or apoptotic cell killing following death 
stimuli depends on the effect the mitochondrial membrane damage has on cellular ATP levels 
(Reed et al, 1998). Damage to mitochondrial membranes can trigger both the abrupt opening 
of a high conductance permeability transition pore in the mitochondrial inner membrane and 
cytochrome c release from these organelles, both of which could lead to interruption of 
electron chain transport causing the generation of ROS, loss of the electrochemical gradient 
across the inner membrane and ATP depletion followed by necrosis (Reed, 1999 and Reed et 
al, 1998) (see Figure 16). As the presence of ATP is essential for the activation of apoptosis 
protease activating factor-1 (Apaf-1) and subsequent activation of caspases that induce 
apoptosis (Pourzand and Tyrrell, 1999), it appears that the high PDT dose insult (i.e. causing 
ATP depletion as a result of severe damage to mitochondrial membrane) as well as glucose 
starvation (i.e. interrupting the main supply of intracellular ATP) could trigger predominantly 
necrotic cell death in treated cells/tissues. Therefore photochemical damage of cellular targets 
involved in energy supply especially mitochondria might play a crucial role in the mode of 
cell death.  
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For example Plaetzer and coworkers (2002) have demonstrated that when human epidermoid 
carcinoma cell A431 is treated with a phthalocyanine-based photosensitiser, the intensity of 
the light dose employed could determine the mode of cell death after PDT depending on the 
changes occurring in mitochondrial function and intracellular ATP. They observed that at 
moderate doses of 2.5-3.5 J/cm
2
, 50% of cells died by either apoptosis or necrosis. However 
at a higher light dose of 6 J/cm
2
, neither caspase 3 activation nor nuclear fragmentation was 
observed and cells died exclusively by necrosis. Necrotic cell death was associated with a 
rapid decline in mitochondrial activity and intracellular ATP. By contrast with apoptosis, the 
loss of mitochondrial function was delayed and the ATP level was maintained at near control 
levels. This study suggests that the magnitude of light dose rather than the photosensitiser 
plays a critical role in the decision of the cell to undergo either apoptotic or necrotic cell 
death. Therefore apoptosis and necrosis may not necessarily be two independent pathways 
but may share common events, at least in early phases of cell death process. This assumption 
is strengthened by a series of studies showing that the magnitude of initial insult of various 
oxidants could be the main determinant of apoptotic and/or necrotic cell death processes (e.g. 
Bonofoco et al, 1995; Hampton et al, 1997).   
 




Figure 16. Mitochondrial damage can induce both apoptotic and necrotic cell death.  The first 
step in the induction of cellular death by various generators of ROS (e.g. PDT and oxidative stress) is 
the increase in mitochondrial membrane permeability and the opening of the mitochondrial 
permeability transition pore that leads to collapse of mitochondrial membrane potential. As a 
consequence of mitochondrial dysfunction, cytochrome C (cyt C) is released from the mitochondrial 
intermembrane space in to the cytosol which acts in concert with ATP to induce conformational 
change in Apaf-1 (apoptotic protease activating factor-1). The conformational change of Apaf-1 
allows it to bind to pro-caspase 9 and form the apoptosome complex. The apoptosome will then act as 
the initiator of downstream caspase cascade activation. However severe damage to mitochondrial 
membrane can trigger the abrupt opening of a high conductance permeability transition pore in the 
mitochondrial inner membrane and cyt C release from these organelles, both of which could lead to 
interruption of electron chain transport causing the generation of ROS, loss of the electrochemical 
gradient across the inner membrane and ATP depletion followed by necrosis. (see Reed et al, 1999). 
(Reproduced from Dr Pourzand‟s slides with permission) (Zhong et al, 2004).  
 
Studies aimed at investigating the pathways of apoptotic cell death induced by the non-
membrane damaging agent staurosporine have already established the importance of ATP in 
the switch between apoptosis and necrosis. Indeed, depletion of ATP by compounds such as 
oligomycin switched the apoptotic cell death to necrosis (e.g. Eguchi et al, 1997; Leist and 
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Nicotera, 1997; Ha and Snyder, 1999), whereas repletion of ATP by glucose or fructose (via 
glycolysis) in the oligomycin treated cells was able to restore the apoptotic cell death.  
An interesting study by Kirveliene and coworkers (2003) demonstrated that intracellular ATP 
concentration correlates with the mode of cell death initiated in murine hepatoma MH22 cells 
in vitro by photosensitisers of mitochondrial but not lysosomal localization: (i) cells 
photosensitised with meso-tetra(4-sulfonatophenyl)-porphine (TPPS4; see section 1.6.4.3 ) 
localized to lysosomes (Boyle and Dolphin, 1996) died mostly by necrosis, and the mode of 
cell death did not depend on the energy metabolism; (ii) cells photosensitised with 
5,10,15,20-tetrakis(m-hydroxyphenyl)-chlorine (m-THPC, see section 1.6.4.2) localized to 
cell membranes including mitochondria (Boyle and Dolphin, 1996), or aminolaevulinic acid 
(ALA, see section 1.6.)-induced endogenous porphyrins predominantly localized in 
mitochondria, under conditions of favorable to glycolysis led to cell death mostly by 
apoptosis, however under conditions unfavorable to glycolysis (i.e. ATP depletion), led to 
considerable decrease in the ratio of apoptosis/necrosis. So in m-THPC- and ALA-mediated 
PDT, intracellular ATP and caspase activation appear to be the downstream controllers 
capable of directing the cells toward either type of cell death i.e. under conditions favorable 
to glycolysis, the intracellular ATP is highly maintained so the PDT insult favours apoptosis 
over necrosis whereas ATP depletion under conditions unfavorable to glycolysis transforms 
apoptosis to necrosis due to inhibition of caspase activation. 
 
Nevertheless, in general in PDT, during illumination the concentration of the photosensitiser 
may decrease due to photobleaching, vasculature stasis, tumour oedema etc. In these 
conditions, as well as in deep tumour regions (illuminated with suboptimal light from the 
very beginning of treatment), the effectiveness of PDT is decreased and tumour cells have a 
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chance to either oppose or repair damage induced by the treatment. If the damage is repaired, 
they will survive the treatment and will contribute to tumour relapse (if not damaged by lethal 
ischaemia or activation of immune response) (Nowis et al, 2005). In all other cases tumour 
cells should undergo apoptosis or necrosis depending on the severity of the PDT insult and 
ATP depletion. However if the damage remains unrepaired, this will lead to mutagenesis. 
 
 
1.6.3. First generation of photosensitisers 
The term „photodynamic therapy‟ was first described in 1903 for oxygen-consuming 
chemical reactions induced by photosensitization in biology (Dougherty et al, 1998). The use 
of porphyrins, the photosensitiser with which the majority of clinical studies have been 
conducted in photodynamic therapy, was introduced in 1961 by Lipson and coworkers. 
During the period from 1961 to 1983, Haematoporphyrin (HP) and its derivatives were the 
most commonly used photosensitiser in PDT research (Bonnett, 1999). Hence these 
tetrapyrroles comprise the first generation of photosensitisers.  
In 1960, Lipson and Baldes attempted to purify and solubilise HP by treatment with 5% 
sulfuric acid in acetic acid, basification and neutralization to pH 7.4 with hydrochloric acid. 
The purified compound, named hematoporphyrin derivative (HPD) had a better affinity for 
tumor tissue than crude HP and could be visualized when injected into the tumour by 
fluorescence endoscopy (Lipson and Baldes, 1961). Early studies very rapidly expanded to 
investigate the phototherapeutic potentials of HPD in preclinical and clinical studies in the 
1970s. In 1972, Diamond and colleagues postulated that the combination of the tumour-
localizing and tumour-phototoxic properties of porphyrins might be exploited to kill cancer 
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cells (Diamond et al, 1972). In 1978, Dougherty and coworkers, demonstrated that parenteral 
HPD administration could be activated by light in the red region of the spectrum (630 nm) to 
cause complete eradication of spontaneous or transplanted mammary tumours in mice and 
rats (Dougherty et al, 1978). Within the same period, Kelly and co-workers reported that light 
activation of HPD also eliminated bladder carcinoma in mice (Kelly et al, 1975). These 
studies classified HPD as the benchmark photosensitiser for the development of forthcoming 
drugs (Kalka et al, 2000; Dolmans et al, 2003). 
 
HPD is a very complex mixture of several components, of which approximately 50% is 
identifiable as oligomeric haematoporphyrins and protoporphyrins. A further chemical 
purification allows for the preparation of porfimer sodium (Photofrin ®), which is a 
lyophilised and concentrated form of monomeric (haematoporphyrin, protoporphyrin and 
monohydroxyethyl-vinyl-deuteroporphyrin) and oligomeric (dimer to hexamer derivatives of 
hematoporphyrin units linked through ether or ester bonds) porphyrins (see Figure 17) and 
reduced fraction of components that are not photoactive. The purified compound Photofrin 
has shown enhanced photosensitising properties (Lui, 1992; Dougherty, 1987). Photofrin was 
the first approved photosensitising drug for clinical PDT of lung, oesophageal, gastric and 
cervical cancer (Evensen, 1995).  
 
 




Figure 17. The chemical structure of porfimer sodium, a complex mixture of monomers and 
oligomers (n=2-6).  
 
The intravenous administration of Photofrin or HPD leads to maximal tumour-to-normal cell 
concentration ratios 24 to 48h after treatment. The absorption spectrum of porphyrins exhibits 
a maximum in the Soret band ranging from 360 to 410 nm, followed by 4 smaller peaks 
between 500 nm and 635 nm (Q bands) (see Figure 18). Unfortunately, significant tissue 
penetration is achieved by light at 630 nm to 635 nm, which corresponds to the weakest of 
the absorption peaks (Stables and Ash, 1995) allowing for a penetration of about 5-10 mm in 
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Figure 18. The absortion spetrum of porphyrins (right) as exemplified by protoporphyrin IX 
(the chemical structure; left). 
 
The cutaneous accumulation of first generation porphyrin-based photosensitising drugs and 
their slow clearance from the skin leads to long-lasting cutaneous photosensitivity, requiring 
photoprotective measures during 4-6 weeks after PDT (Gomer, 1991). An approach to avoid 
this side effect is the use of topical formulations (e.g. Steiner et al, 1995). However the 
number of reports is very limited and major studies using PDT with topical first generation 
photosensitisers are lacking (Kalka et al, 2000). 
 
The poor selectivity of first generation photosensitisers between tumour and normal tissue 
and their long clearance time that led to prolonged skin photosensitivity in subjects 
encouraged the investigations to design improved synthetic photosensitisers for PDT. These 
compounds are referred to as „second generation photosensitisers‟.      
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1.6.4. Second generation of photosensitisers 
Following the initial successful attempts to treat specific cancers with PDT, a number of 
second generation photosensitisers have been developed. In contrast to Photofrin and HPD 
which are mixtures, these drugs are pure substances and present a higher absorbance in the 
far red (660-700 nm) or near infrared (700-850 nm) regions of the spectrum. The higher 
molar absorption coefficient results in a more intense excitation of the photosensitiser at a 
wavelength that also allows a deeper penetration into tissues (up to 20 mm compared to 5-10 
mm at 630 nm) and consequently a more efficient therapeutic effect (provided that sufficient 
oxygen is available) (Nyman and Hynninen, 2004; Wilson et al, 1984). In addition, near-
infrared absorbing photosensitisers should allow for the treatment of highly pigmented 
tumours such as melanoma metastases, which are unaffected by photosensitisers that absorb 
in the visible range. Light with a wavelength longer than 850 nm is not used because it does 
not yield enough energy to trigger a photochemical reaction (Calzavara-Pinton et al, 2007).  
 
The second generation of photosensitisers includes many families of molecules such as 
modified porphyrins, bacteriochlorins, phtalocyanines, naphtalocynanies, pheophorbides and 
purpurins. Most of these photosensitisers are used as PDT agents in clinical trials (Stemberg 
et al, 1998) for various cancers, including cutaneous malignancies. A brief description of 
these photosensitisers in provided below. Figure 19 illustrates the chemical structure of some 
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Figure 19. Chemical structure of some of porphyrin-derived sensitisers (Modified from 
Calzavara-Pinton et al, 2007).  
 
1.6.4.1. Phthalocyanines:  
The joining of four benzene or naphthalene rings to the α-pyrrolic position of porphyrins and 
substituting the methane bridge carbons with nitrogen produces phthalocyanines and 
naphthalocyanines (see Figure 20). Because these compounds absorb long wavelength light 
strongly, they can be used at much smaller doses than Photofrin (i.e. at a dose 4-5 fold lower 
than Photofrin). Furthermore as phthalocyanines and naphtalocyanines do not strongly absorb 
light in the 400-600 nm range, they therefore provide a lower risk of generalised 
photosensitivity to sunlight than porphyrins (Moan and Berg, 1992; Jori, 1992). 
 




Figure 20. Chemical structure of phtalocyanines and naphtalocyanines that are relevant to 
PDT. (source: Nyman and Hynninen, 2004).  
 
Phthalocyanines show promises for PDT of cancer. The incorporation of diamagnetic metals 
such as Zn or Al into the phthalocyanine macromolecule increases the half-life of triplet state 
and guarantees a satisfactory yield of 
1
O2 generation for efficient photosensitisation and 
phototoxicity in the target tissue (Jori, 1992). Examples include the phthalocyanine derivative 
AlPcS2 (chloroalmunium sulphonated phthalocyanine). These compounds have higher 
chemical stability, superior direct tumour cell phototoxicity and a strong absorption peak in 
the red spectrum (650-700 nm), that provide deeper penetration into the tissue as compared 
with porphyrins (Spikes, 1986; Oleinick et al, 1993; Rosenthal, 1991). These properties 
coupled with negligible dark toxicity, and excellent photodynamic activity at increased 
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wavelengths has led to the clinical evaluation of phthalocyanines notably AlPcS2 for PDT 
(Ben-Hur, 1992; Gerber-Leszczyszyn et al, 2004). Neverthelass the slow rate of clearance of 
AlPcS2 may cause the problem of photosensitivity for topical applications of the compound 
for skin cancer lesions (Peng and Moan, 1995).  
 
1.6.4.2 Chlorin and Bacteriochlorin derivatives:  
The reduction of a peripheral double bond of porphyrin strengthens the longest wavelength 
band and moves the absorption peak to the red. The dihydroporphyrins thus obtained are 
called „chlorins‟ (Nyman and Hynninen, 2004) (see Figures 19 and 21). Among chlorin 
derivatives, the meta-tetrahydroxyphenyl chlorine (m-THPC) was originally introduced in 
clinical trials for the treatment of mesothelioma and is now widely used in many countries to 
treat respiratory, gynaecological and head and neck cancers (Hopper, 2000 and Figure 19). 
The photosensitiser m-THPC (Temoprofin, Foscan®; Biolitech Pharma, Edinburgh, 
Scotland, UK) is a pure compound whose effectiveness in PDT has been reported as a 200-
fold higher than Photofrin (Sharman et al, 1999). Compared to Photofrin, it is excited at a 
longer wavelength (i.e. 650 rather than 630 nm) and has a higher molar absorbance 
coefficient (i.e. 15-fold higher). It has also a longer half-life than Photofrin in the excited 
state and its higher hydrophobicity facilitates cellular uptake and as a result its use for clinical 
indications has been extensively investigated (e.g. Copper et al, 2003) for head and neck SCC 
and (e.g. Campbell et al, 2004) to target intraepithelial lesions. The comparative in vitro 
studies on the dark and light-dependent cytotoxic effects of m-THPC formulations with other 
second generation photosensitisers has proven the reputation of this chlorin as very effective 
photosensitiser. Fospeg®, a water soluble formulation of m-THPC, shows a strongly reduced 
dark toxicity and a similar phototoxic efficiency compared to Foscan®. Foscan® and 
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Fospeg® induce apoptosis in epidermoid carcinoma cells, A431 over a relatively wide range 
of fluences (Allison et al, 2004; Berlanda et al, 2010). Due to their efficacy and absorption at 
654 nm they could be both suitable for treatment of malignancies characterised by a greater 
extension; for example a tumouricidal depth of up to 8 mm has been demonstrated for 
pancreatic cancer (Bown et al, 2002). Nevertheless the residual photosensitivity of m-THPC 
is comparable to that of Photofrin (Palumbo, 2007). 
 
 
Figure 21. Chemical structure of meta-tetrahydroxyphenyl chlorine (m-THPC) 
 
Other chlorin derivatives such as mono-L-aspartyl chlorin e6 (NPe6, Porphyrin Products Inc, 
Logan UT, USA) was reported to have high effectiveness in clinical trials (e.g. Wong et al, 
2003) (see Figure 22). Although this compound provokes only a very mild and transient 
photosensitivity, for adequate tumour response it requires high photosensitiser concentration 
that results in a decrease in tissue selectivity.  Both NPe6 and chorin e6 (Dialek LTd, Minsk, 
Belarus) are hydrophilic compounds with similar photobiological properties. They have been 
investigated as photosensitisers in dermatology for the PDT of various cutaneous and 
subcutaneous malignancies, including recurrent adenocarcinoma of the breast as well as basal 
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cell carcinoma (BCC) and squamous cell carcinoma (SCC)  (e.g. Taber et al, 1998; Gomer 
and Ferrario, 1990; Calzavara-Pinton et al, 1998; Sheleg et al, 2004). 
                                         
Figure 22. Chemical structure of mono-aspartyl chlorin e6 (NPe6) 
 
Purpurins contain the porphyrin macrocycle and have absorption bands of 630-715 nm (see 
Figure 23). Among purpurins, Tin etiopurpurin (SnET2) is a synthetic chlorin analogue with 
maximal excitation at 660 nm (Wilson and Mang, 1995). It is a mild photosensitiser and it 
takes few days after the treatment to clear from the skin, although cutaneous reactions 
occurring one or more months after PDT have been reported (Morgan et al, 1988; Garbo et 
al, 1996). Nevertheless SnET2 has been used successfully for the photodynamic management 
of BCC, Bowen‟s disease (BD), cutaneous metastatic breast cancer and AIDS-related Kaposi 
sarcoma (e.g. Bissonnette and Lui, 1997; Wilson and Mang, 1995). 
 
A number of companies are also developing promising bacteriochlorins with improved 
optical properties absorbing light at more than 740 nm that might be particularly useful for 
PDT of pigmented tumours (Jori, 1992 and Figure 23). Among these compounds, SQN400 
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(trade name for meta-tetra-hydroxyphenyl bacteriochlorin; mTHPBC) has recently been used 
in some clinical Phase I studies (e.g. van Duijnhoven et al, 2005) (see Figure 24). 
 
 
Figure 23. Completely synthetic chlorin and bacteriochlorin derivatives that have been 
proposed for PDT. (source; Nyman and Hynninen, 2004). 
 
Figure 24. Chemical structure of meta-tetra-hydroxyphenyl bacteriochlorin (mTHPBC) 
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1.6.4.3 Other porphyrin- and chlorophyl-derived photosensitisers:  
Porphines are synthetic porphyrins that have been shown to have high photosensitising and 
anti-mitotic potency in tumours (Kreimeier-Birnbaun, 1989). Topical TPPS4 (tetra-sodium-
meso-tetraphenylporphine-sulfonate) has been evaluated intensively for the treatment of skin 
tumours (Santoro et al, 1990). The hydrophilic compound is activated by light at 630 nm and 
localizes preferentially in the tumour stroma (Kessel et al, 1987). It is 25-30 times more 
effective than HPD and Photofrin as photosensitiser (Calzavara-Pinton et al, 2006). The 
major limitation of TPPS4 is its neurotoxicity (Lui and Anderson, 1992). 
 
Benzoporphyrin derivative monoacid ring A (BPD-MA), also known as Verteporphin 
(Visudyne®, Novartis AG, basel) is a semi-synthetic porphyrin derived from protoporphyrin 
(Henderson and Dougherty, 1992) (see Figure 25). This photosensitiser has poor solubility 
but can be formulated successfully either in liposomes or emulsions (Knabler et al, 1999). 
The absorbance peak for PDT occurs at 650 nm. BPD-MA has important applications in the 
treatment of choroidal neovascularisation in age-related macular degeneration (AMD). The 
photosensitiser BPD-MA has also found potential applications in dermatology especially for 
PDT of BCC and SCC (Kalka et al, 2000). Recent studies (Phase III clinical trials, see 
Gerber-Leszczyszyn et al, 2005) have shown that injectable BPD-MA possesses a significant 
and rapid accumulation in the tumour low residual skin photosensitivity and the overall 
cosmetic effect is acceptable. 
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Figure 25. Chemical structure of benzoporphyrin derivative monoacid ring A (BPD-MA) 
 
Porphycenes are structural isomers of porphyrins and texaphyrins are modified porphyrins in 
which a phenyl ring replaces one pyrrole ring. Both porphycenes and texaphyrins generate 
1
O2 efficiently (Kreimer-Bimbaum, 1989). Porphycenes possess high fluorescence yields and 
show a 10-fold increase in light absorption at 630 nm when compared with HPD (Kreimer-
Bimbaum, 1989). As a result they are considered potentially useful as diagnostic tools 
(Palumbo, 2007). The porphycene dye 9-acetoxy-2,7,12,17-tetrakis-methoxyethyl-porhycene 
has also been assayed for potential topical application in skin lesions (Karrer et al, 1997) (see 
Figure 26).  
 
Figure 26. Chemical structure of 9-acetoxy-2,7,12,17-tetrakis-methoxyethyl-porphycene. 
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Texaphyrins can easily be complexed with large metal cations such as Lu(III) to give metal 
complexes that are photoactive in vivo (Nyman and Hynninen, 2003). The Lu(III)-complex of 
a texaphyrin (Lu-Tex, Lutryn®, Pharmacyclics Inc., CA, USA; see Figure 27) is a very 
stable hydrophilic photosensitiser. It is a highly fluorescent dye and absorbs strongly at 732 
nm (Woodburn et al, 1996), and rapidly accumulates in neoplastic tissue allowing irradiation 
as early as 2-4h after drug administration (Kalka et al, 2000). The lack of significant 
persistent skin phototoxicity is another outstanding characteristic of these compounds 
(Sessler and Miller, 2000). Preliminary results based on the therapy of various malignancies, 
such as recurrent breast cancer, invasive SCC, malignant melanoma, Kaposi‟s sarcoma and 
BCC have demonstrated best response rates in breast cancer lesions and partial responses in 
other treated tumours (Renschler et al, 1997). Lu-Tex has also been subject of clinical trial in 
patients with locally recurrent prostate cancer (Palumbo, 2007). Nevertheless Lu-Tex can 
cause severe cutaneous pain during PDT (Kreimer-Bimbaum, 1989).  
 
Figure 27. Chemical structure of Lu(III) texaphyrin (Lu-Tex). 
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Pheophorbides are a group of chlorophyll-derived photosensitisers. Within this group of 
photosensitisers Palladium-bacteriopheophorbide has been used to treat human prostatic 
small cell carcinoma (Koudinova et al, 2003) and 2-[1-hexyloxyethyl]-2-devinyl 
pyropheophorbide-a (HPPH) has been assessed successfully in Phase II clinical trial 
(NCT00281736) for the treatment of oesophageal cancers with very mild skin 
photosensitivity declining rapidly within days (Bellinier et al, 2006). HPPH-23 is another 
promising photosensitiser which has been successfully used in PDT of SCC in animal studies. 
It also appears to be a potent drug for the management of skin cancer. HPPH-23 can also be 
cleared rapidly from normal skin (Magne et al, 1997).  
Finally, Hypericin (see Figure 28) a naturally occurring substance found in plants 
(Hypericum perforforatum) is a promising PDT agent for the treatment of cancer with strong 
photosensitising properties, a high yield of 
1
O2 and fluorescence emission. These properties 
has made hypericin a powerful diagnostic tool for example in the photodiagnosis of small 
tumor of urothelium (Kubin et al, 2005; Olivo et al, 2003; Palumbo, 2007).   
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1.6.5. Topical photosensitising mediators: α-Aminolaevulinic acid and–esters  
Another method of photosensitising cells is to stimulate the synthesis of endogenous 
photosensitisers notably the haem immediate precursor PPIX. This method of sensitising 
tumours with an intermediate of the haem biosynthetic pathway i.e. ALA was originally 
proposed by Malik and Lugaci in 1987.  
PPIX is an efficient photosensitizer and its rate of formation is dependent on the rate of ALA 
synthesis (see Figure 29) from glycine and succinyl coenzyme A which in turn is regulated 
in a negative feedback manner by the concentration of the final product heme.  
 
Figure 29. Synthesis of α-aminolaevulinic acid (ALA) from glycine and succinyl coA by ALA-
synthase.   
As the conversion of PPIX to haem is rather slow, administration of exogenous ALA can 
bypass the negative feedback control of haem biosynthesis, leading to intracellular 
accumulation of photosensitizing concentrations of PPIX. The resulting photosensitization 
provides a basis for using ALA-induced PPIX for photodynamic therapy (PDT) of cancer 
 
δ 
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(Kennedy et al, 1990; Wolf and Kerl, 1991; Peng et al, 1992). Typically, ALA 
supplementation into tumour tissue is followed by red (630-635 nm) or blue (380-420 nm) 
light treatment of the tumour tissue. In the ideal situation, photochemically generated ROS 
thus formed will destroy the tumour tissue while sparing the surrounding normal tissue.                     
The fluorescence of ALA-induced PPIX can also be used for the purpose of diagnostic 
detection of tumor cells, such as in early stages of skin malignancies. This procedure, termed 
photodynamic diagnosis (PDD), aids delineating poorly defined tumor borders before the use 
of invasive treatment modalities.  
 
1.6.5.1. Haem biosynthesis pathway 
Figure 30 illustrates the haem biosynthetic pathway. Briefly, the enzymatic condensation of 
glycine and succinyl-CoA to ALA by ALA-synthase (ALAS) is the initial and rate- 
determining step of haem synthesis, which is regulated by haem through a negative feedback 
mechanism. The enzyme ALAS is located on the matrix side of the inner mitochondrial 
membrane loosely associated with the membrane (May and Bawden, 1989). Once in the 
cytoplasm, ALA is metabolized by ALA dehydratase (ALA-D), which induces the 
condensation of two molecules of ALA to yield porphobilinogen (PBG). The combined 
action of PBG deaminase (PBGD) and uroporphyrinogen III co-synthase condenses in a 
head-to-tail manner four molecules of PBG and cyclises the tetrapyrrole chain to form 
uroporphyrinogen III (Xu et al, 1995). Uroporphyrinogen decarboxylase then removes four 
acetic acid carboxy groups to form coproporphyrinogen III (Moore et al, 1987). The 
subsequent steps in the mitochondrion result in the build up of PPIX. The final step of haem 
synthesis is the incorporation of iron into PPIX which is catalysed by ferrochelatase in the 
inner mitochondrial membrane. If an excess of PPIX is synthesized, it can diffuse from the 
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mitochondrion into the endoplasmic reticulum and also into the plasma membrane, both 
which are the other known sites of cellular damage through PDT (Barr et al, 2002).  
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1.6.5.2. Advantages of topical ALA-PDT 
The main advantage of using topical ALA-PDT is the absence of prolonged cutaneous 
photosensitivity when compared to systemic HPD/Photofrin-PDT (Peng et al, 2001). While 
with ALA-PDT there is no risk of skin photosensitivity after 24h, with HPD/Photofrin PDT, 
the photosensitivity of the skin is sustained for at least 4-6 weeks after treatment and unlike 
ALA-PDT modality, patients treated with HPD/Photofrin-PDT often stay in hospital for few 
days after the therapy. Furthermore ALA-PDT is a relatively low cost modality as ordinary 
lamps with suitable filters can be used whereas HPD/Photofrin-PDT treatment is rather 
expensive as a laser is used in most cases. ALA-PDT has also a high selectivity leaving the 
surrounding normal skin intact and functional. Furthermore several separate lesions can be 
treated simultaneously by ALA-PDT and if necessary the same lesions can be repeatedly 
treated. Cosmetic results of ALA-PDT is also superior to conventional modalities (Peng et al, 
2001), however compared to HPD/Photofrin-PDT, it is more efficient for superficial lesions 
than nodular lesions (Peng et al, 1997). The optimal application time and the ALA 
concentration in ALA-PDT, depends on the characteristics of the targeted cells. The 
abnormal stratum corneum shows increased permeability to ALA, which is partly responsible 
for the tumor selectivity. Ironically, this phenomenon contributes to the major limitation of 
ALA-PDT; the poor ALA penetration through intact keratinised surfaced layers of nodular 
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1.6.5.3. ALA and ALA-esters uptake and cytotoxicity   
A partial drawback of ALA as a photosensitiser is its hydrophilic nature, which limits its 







dependent -amino acid, including glycine and γ-aminobutyric acid 
(GABA) transporters (Rud et al, 2000). These systems require energy, depend on pH and 
temperature and although they are slightly accelerated in tumour cells, in general they are 
considered as saturable and slow processes (Klock and van Henegouven, 1996; Gaullier et al, 
1997; Uehlinger et al, 2000). This problem has been in part reduced by the use of lipophilic 
ALA-esters notably methyl-aminolaevulinate (MAL) which accumulates selectively as ALA 
in neoplastic tissue and seems to penetrate the skin rapidly and deeply. For example it has 
been shown that, in WiDr adenocarcinoma cells, MAL is taken up by active mechanisms 
mainly through transporters of non-polar amino acids such as L-alanine, L-methionine, L-
tryptophan and glycine (Gederaas et al, 2001). Most importantly, MAL is also taken up by 
passive transmembrane diffusion. This mechanism that does not require energy, is 
unsaturable and is also very efficient in normal cells and even more so in neoplastic cells. 
The plurality and efficiency of these diverse mechanisms determine the enhanced penetration 
characteristics of MAL in comparison to ALA. This difference is even more significant in 
malignant cells (Peng et al, 1997). Soon after cell penetration, MAL is rapidly demethylated 
to ALA and therefore the subsequent metabolic steps remain the same (Gaullier et al, 1997). 
In addition, ALA-ester derivatives achieve the maximum in intracellular PPIX concentration 
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1.6.5.4. Light Sources for topical ALA/MAL-PDT 
Table I provides an overview of light sources used in PDT. The first light sources used in 
PDT were non-coherent light sources (Klein et al, 2008). Since then, numerous studies have 
demonstrated the effectiveness of long-pulsed dye lasers (Klein et al, 2008). Along with 
much shorter exposure times, the laser sources also allow the user to select the optimal 
wavelength. Flash-lamps are also commonly used in PDT of AK, photorejuvenation and acne 
vulgaris (Alexiades-Armenakas, 2006).  
Table 1: Common light sources for PDT  
Non-coherent lamps Laser Other 
- Xenon lamps  
  (400-1200 nm) 
- Halogen lamps  
(560-800 nm) 
- Pulsed dye laser (PDL)     
  (585 nm) 
- Long-pulsed dye laser  
  (595 nm) 
- Argon dye laser (ADL)  
(450-530 nm) 
- Diode laser  
(800-1000 nm) 
- Intense pulsed light (IPL)   
   (500-1200 nm) 
- Light emitting diode (LED)  
   (631 ± 2 nm) 
-Fluorescence diagnosis systems 
Note: Modified from Klein et al, 2008 
Photodynamic management of dermatologic conditions is simplified by the accessibility of 
the skin to light application and leaves the option to use any light device with the appropriate 
spectrum corresponding to the absorption maximum of the photosensitiser. The popular 
filtered slide projectors are now gradually being replaced by non-coherent sources 
constructed especially for their use in PDT. The PDT 1200 lamp (Waldmann) is a metal 
halogen lamp which emits 600 to 800 nm radiation at light power density; keeping light 
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exposure times within practical limits (Stables, 1995). Another alternative light device is the 
short-arc xenon lamp, tunable over a band width between 400 and 1200 nm. (Whitehurst et 
al, 1993). Non-coherent light sources are safer, easy to use, and less expensive. They can 
produce spectra of wavelengths to accommodate various photosensitisers. The broad light 
beam produced by non-coherent lamps is useful for the treatment of large lesions using ALA-
PDT. However the lower radiation power at the periphery of the treated lesion as opposed to 
the centre of the irradiation area may result in insufficient treatment of the tumour borders 
(Karrer et al, 1995). When multiple lesions are located on a convex surface (e.g. multiple AK 
on the scalp), it is necessary to deliver light from multiple directions to ensure the 
illumination of all the lesions.  
Non-coherent light sources can be used in conjunction with optical filters to output selective 
wavelengths. The disadvantages of conventional lamps include significant thermal effect, low 
light intensity and difficulty in controlling light dose. However, nowadays, most of these 
drawbacks can be overcome by careful engineering design. For example it is known that non-
laser light sources emit significant fluences of infrared radiation together with light useful for 
PDT (Stringer et al, 1995). Infrared radiation should be filtered out to avoid hyperthermia, 
although some investigators find that mild hyperthermia (40-42
o
C) acts additively or 
synergistically with PDT (Waldow and Dougherty, 1984; Kimel et al, 1992). To avoid 
hyperthermia, a fluence rate lower than 150 mW/cm
2
 is recommended (Peng et al, 1997). 
As it can be seen in Figure 18, PPIX has its largest absorption peak in the blue region of 405-
410 nm (Soret band), with smaller absorption peaks at 505, 540, 580 and 630 nm. Most light 
sources for ALA/MAL-PDT aim to utilise the 630 nm in the red region to improve the tissue 
penetration. However a blue fluorescent lamp called the BLU-Ulight illuminator (DUSA 
Pharmaceuticals, Inc), (peak emission 417 nm) is now routinely used in Levulan ALA-PDT 
of AK in USA. There are now several reports that blue, green and red light can each be 
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effective in topical PDT of AK, but more deeply penetrating red light is superior when 
treating BD and BCC (Morton et al, 2002). 
As ALA-PDT is mostly used in the treatment of tumours at the surfaces of organs (i.e. the 
skin, bladder and aerodigestive tract), lamps may be as well suited as lasers. In contrast to 
traditional incandescent lamps, lasers provide the exact selection of wavelengths matching 
the absorption of the photosensitiser and the precise application of light. The tunable argon-
dye laser (ADL) is composed of an argon laser that emits a blue-green beam in the 450-530 
nm range, pumping a dye laser to obtain light in the range of desired wavelength (Kalka et al, 
2000). The ADL system emits light continuously and is tunable to suit the absorption 
properties of various photosensitising compounds (350-700 nm), representing the most 
popular light device used in PDT (Fisher et al, 1995).  
Non-laser sources are popular in topical PDT, possessing the advantages over lasers of being 
inexpensive, stable, and easy to operate, requiring little maintenance and providing wide area 
illumination fields. Retrospective comparison of laser and filtered broadband sources 
suggests equivalent efficacy in topical PDT (Clark et al, 2003). Currently a range of non laser 
light sources, doses and irradiations continues to be used in ALA-PDT, in comparison to 
MAL-PDT which typically involves light emitting diode (LED) source.   
In the last few years, LED sources have undergone considerable development, with 
improvements in design making these relatively inexpensive sources convenient for wide 
area irradiation and popular for patient use, e.g. the Aktilite 16 and 128 (Galderma, France) 
and the Omnilux (Phototherapeutics Ltd, Altincham, UK). These LED sources match the 
630/635 nm activation peak of PPIX while excluding the extraneous wavelengths in 
broadband sources, thus permitting shorter irradiation times. Biophysical calculations 
indicate that LED source with peak emission of 631± 2 nm may have a deeper PDT action in 
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tissue than a filtered halogen type lamp of 560-740 nm emission, and hence LED may be 
more effective in treating the deeper parts of tumours (Juzeniene et al, 2004). LED can 
generate high energy light of desired wavelengths and can be assembled in a range of 
geometries and sizes.  Babilas et al (2006) compared the effectiveness of a non-coherent light 
source with an LED system. In vitro cultured human epidermal keratinocytes were incubated 
for 24h with various ALA concentrations and then exposed to either incoherent or LED light. 
No significant difference was observed in cytotoxicity induced by the two light sources. In a 
subsequent in vivo investigation, patients with at least two AK lesions were exposed to these 
light sources (i.e. half to each light source). There was again no significant difference in 
remission rates, pain or cosmetic results (Klein et al, 2008). In another study, Babilas et al 
(2007) compared an LED system with a flash-lamp (VPL, variable pulsed light; Energist 
Ultra VPL
TM
, Energist Ltd, Swansea, UK) for the MAL-PDT of AK. Both lamps were 
similarly effective, although pain during and after treatment was significantly lower on the 
side of face treated with the flash-lamp than on the side exposed to LED.  
A series of studies have suggested that pulsed light therapy may be useful for treatment / 
adjunctive treatment in topical PDT of acne vulgaris, AK and photorejuvenation (Morton et 
al, 2008). However a recent controlled investigative study performed in healthy human skin 
in vivo following microdermabrasion and acetone scrub, showed that two pulsed light sources 
previously reported in PDT, the PDL and a broadband flashlamp filtered intense pulsed light 
(IPL), produced evidence of minimal activation of photosensitiser, with a dramatically 
smaller photodynamic action than seen with a conventional wave broadband source 
(Strasswinner and Grande, 2006). Furthermore IPL and PDL sources deliver intense light in 
periods (i.e. 20 ms), which might suppress oxygen consumption (Kawauchi et al, 2004). 
Buchczyk et al (2001) also compared the effectiveness of ALA-PDT in a human cultured 
skin fibroblasts with three different light sources of (i) red light source (570-700 nm; 
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PDT1200 illuminator, Waldmann Litchttechnik, Germany) at an intensity of 50 mW/cm
2
;  (ii) 
green light source (545 ± 3 nm; PDT Green Light, Saalmann, Herford, Germany) at 
intensities of 10-20 mW/cm
2
; (iii) UVA light (320-400 nm; UVA700 illuminator, Waldmann 
Lichttechnik, Villingen, Germany) at intensities of 44 (without ALA) and 10 mW/cm
2
 (with 
ALA). The results showed that compared with red light source, UVA-ALA-PDT was 40-fold 
more potent in killing cultured human skin fibroblasts and still 10-fold more potent than 
ALA-PDT with green light. The high cytotoxicity of UVA-ALA-PDT relied on the efficient 
formation of 
1
O2 as was demonstrated with modulators of 
1
O2-half-life. So, ALA-PDT in the 
UVA region might be preferable to red or green light ALA-PDT for treatment of readily 
accessible tissue because of its higher efficiency. The latter study further justifies the use of 
blue light for ALA-PDT of superficial skin lesions such as AK. Although in most cases of 
ALA-PDT, light at 630 nm is applied, light in the Soret band (410 nm) is a powerfull 
alternative as it would give the largest cell inactivation down to about 2 mm from the surface 
in human skin and muscle tissues as well as in superficial BCC. However at depths exceeding 
2 mm, 635 nm light might be a better option than blue light (Szeimies et al, 1995; Peng et al, 
1997).   
 
1.6.5.5. Dermatologic applications of ALA/MAL-PDT 
Non-melanoma skin cancer (NMSC) is the most common cancer in UK, with official figures 
reporting over 72,400 cases diagnosed only in 2004 (Neville et al, 2007). The vast majority 
of NMSC is Basal Cell Carcinoma (BCC) which comprises 75% of all NMSC cases (Neville 
et al, 2007).  Squamous Cell Carcinoma (SCC) is the second most common type of skin 
cancer in this country (i.e. 20% of skin cancers) (Neville et al, 2007). In the USA, one million 
new cases of NMSC are diagnosed each year and of these 80% are BCC and 16% are SCC 
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(Neville et al, 2007). The incidence of SCC is increasing across Europe, the USA and the 
Southern hemisphere (Neville et al, 2007; Schmook and Stockfleth, 2003) and the incidence 
of BCC continues to rise in Australia; it is estimated that NMSC affects at least 1-2% of the 
population annually (Schmook and Stockfleth, 2003; Marks, 1997).  
BCC may be categorized into three major growth patterns: nodular (nBCC), superficial 
(sBCC) and morphoeiform (or sclerotic; mBCC). Superimposed on any of these growth 
patterns may be ulceration or pigmentation. Metastasis is extremely rare and the morbidity 
associated with BCC is related to local tissue invasion and destruction, particularly on the 
head and neck. Most sBCCs will progressively enlarge over months to years and with time, 
may adopt nodular or even sclerotic growth patterns. nBCCs that are often found on the head 
and neck of old subjects will also progressively enlarge with tendency to deep extension and 
ulceration. In contrast, mBCCs have a sclerotic growth pattern with the appearance of pale 
scar that tends to be deeply invasive, making surgical and non-surgical treatments less 
effective (Albert and Weinstock, 2003).  
Exposure to UV is the most important risk factor of NMSC and is related to sun-exposure 
habits. Light complexion, increasing age, male gender, immunosuppression, ionizing 
radiation and psoralen phototherapy and precancerous skin lesions are other host factors 
(Albert and Weinstock, 2003). Among precancerous skin lesions, Aktinic keratoses (AK) that 
are potential precursors of SCC are very common with an incidence about 10-fold that of 
BCC (Harvey et al, 1996). In Australia, it has been estimated that 60% of the population over 
the age of 40 years will have at least one AK lesion (Schwartz, 1997). AK lesions could 
affect the face, scalp, hands and forearms in the form of small, dry, rough yellow-brown 
lesions with well-defined scales that do not flake off.  They may become thick and horny and 
sometimes bleed. Pathological evidence suggests that AK should be regarded as very early 
SCC (Czarnecki et al, 2002). As 3-4% of SCCs metastasize (Lober and Lober, 2000), it has 
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been suggested that AK should be treated early to avoid malignancy and the need for more 
extensive treatment. 
Among NMSC conditions, Bowen‟s disease (BD) is also a persistent form of intra-epidermal 
(in situ) SCC, which appears as an enlarging, well-demarcated, erythematous plaque with an 
irregular border, a crusted or scaling surface and potential for extending along the cutaneous 
appendages. Nevertheless BD has a small potential for invasive malignancy (Morton, 2005).  
As the incidence of NMSC increases, so does the number of modalities used to treat this 
condition. Surgery is the most common approach with the Mohs micrographic surgery being 
the best treatment so far, but owing to the time and expense involved with this procedure, it is 
indicated only in patients with aggressive tumours. Apart from surgical excision, cryotherapy, 
curettage and electrocautery are practiced. Radiation therapy is also effective but its use is 
limited because of the side effects. Several regimens of chemotherapy have been clinically 
applied for the treatment of NMSC but have turned out to be insufficient at improving the 
prognosis (Cassileth and Chapman, 1996; McCann 1997). Further non invasive options for 
NMSC include topical chemotherapeutics, biological immune response modifiers and 
retinoids which can be used particularly in patients with superficial tumors. Treatments so far 
are tailored to tumor type, location, size and histological pattern but with increasing incidence 
of NMSC, there is a clear need to design new non invasive treatments to target cancer cells 
more generally at all stages of tumorigenesis.  
PDT with topical ALA/MAL formulations represents one of the most promising treatments 
for NMSC (Cairnduff et al, 1994 ; Fink-Punches et al, 1997; Omrod and Jarvis, 2000;. Peng 
et al, 1997; Lehmann, 2007; Morton et al, 2001; Morton, 2005).  
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MAL (Metvix®, Photocure ASA, Oslo Norway and Galderma SA. Paris, France) is presently 
approved for use in Europe with combination with red light for treating AK, superficial and 
nodular BCC and BD. In the United States, a combination of an alcohol-containing ALA 
solution in a special applicator (Levulan Kerastick®, DUSA Pharmaceuticals Inc., USA) with 
blue light (417 nm) has been approved for clinical treatment of AK (Klein et al, 2008). 
Clinical studies have revealed that overall clearance rates for the treatment of AK with 
ALA/MAL-PDT ranges from 50% to 71% when one treatment is performed and up to 90% 
when two or more treatments are performed. Clearance rates for BCC using ALA/MAL-PDT 
range from 76-97% for superficial tumors to 64-92% for nodular BCC (Tierney et al, 2009). 
Because of the significant results obtained from preclinical and clinical studies (Hongcharu et 
al, 2000), in 2003, ALA-PDT was also approved for moderate inflammatory acne vulgaris in 
USA.  
Preclinical and clinical studies have also demonstrated the great potential of ALA/MAL-PDT 
for treatment of Mycosis fungoides (Stables et al, 1997). Other dermatological applications 
include human papilloma virus-associated cutaneous pathologies, lymphocytoma cutis, 
leishmaniasis, alopecia areata, erythroplasia of Queyret and benign familial pemphigusand 
hidradentis suppurativa (see Tierney et al, 2009; Kalka et al, 2000; Huang 2005). A number 
of other non-malignant conditions such as psoriasis, viral warts and hair removal have also 
been under clinical investigation internationally for more than a decade (Robinson et al, 
1999; Stender et al, 1999; Stender et al, 2000; Hongeharu et al, 2000; Robinson et al, 1999; 
Huang, 2005). Clinical investigations of ALA-PDT have also extended to basaloid follicular 
hamartomas, cutaneous T-cell lymphoma and sebaceous gland hyperplasia in recent years 
(Leman et al, 2002; Horio et al, 2003; Coors et al, 2004; Gold et al, 2004; Oseroff et al, 
2005). In addition to preventing the development of scars and dyspigmentation that occurs 
with surgery, ALA-PDT has the added benefit of photorejuvenation (Alster et al, 2005) and 
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has been used as a treatment to soften (Alster et al, 2005) the appearance of acne scars as 
well as fine lines and wrinkles of photodamaged skin (e.g. Alster et al, 2005; Dover et al, 
2005).   
 
1.6.5.6. Approaches to improve the uptake of ALA and MAL from skin lesions for 
efficient PDT response   
Table 2 provides the product name and ingredients of some ALA preparations used in PDT 
of skin lesions.  It is clear that optimisation of topical formulations of ALA and MAL will 
almost certainly improve the efficiency of ALA/MAL-mediated PDT. Christiansen and 
colleagues (2007) recently published a study on the fluorescence pattern of 20% ALA in a 
cream vehicle when compared to 0.5% and 1% ALA in a liposomal vehicle using ten young 
subjects with healthy skin. The comparison of fluorescence values between the two 
preparations showed that the maximum fluorescence for liposomal cream was already 
achieved after 2h, however in cream-based ALA, the maximum effect was only reached after 
8h. The superior penetration of liposomal formulations of ALA may also lead to significantly 
decreased ALA concentration needed for PDT. Several PhaseII / III clinical trials are now 
underway for the use of liposomal or nanocolloidal ALA (e.g. BF-200 ALA, Biofrontera AG, 
Leverkusen, Germany) preparations for the treatment of AK (Klein et al, 2008).  
Hyperkeratosis is often the reason for a poor response to topical ALA/MAL-PDT of skin 
lesions notably AK and BCC. Limited uptake of topically applied ALA/MAL and suboptimal 
production of PPIX may account for these differences.  A time-consuming aspect of ALA-
PDT of skin lesions is the removal of crusts with a curette (keratolysis) to improve 
penetration and decrease the incubation time of ALA or MAL (Thissen et al, 2000; Morton, 
2003; Moore and Allan, 2003). Overnight incubation with an ointment for easy mechanical 
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removal might also be beneficial. Other modalities include the use of keratolytics, tape 
stripping, microdermabrasion or laser ablation (Klein et al, 2008) Penetration enhancers may 
also beneficial as they may alter the composition or organisation of the intracellular lipids of 
the stratum corneum. Several studies have been performed on the use of DMSO, azone, 
glycolic acid, oleic acid and ionotophoresis to increase the penetration of ALA (Ziolkowski et 
al, 2004; Orenstein et al, 1996; Ibboston et al, 2006; Lopez et al, 2003). One possibility is to 
administer ALA via topically applied patch (PD P 506, photonamic GmbH & Co KG, Wedel 
Germany). This possibility is presently subject of a multicentric Phase II clinical trial in 
Germany with patients suffering with AK (Klein et al, 2008; Donnelly et al, 2010).  
Table 1: ALA Preparations  
Product Name Ingredients 
Metvix® 16% methyl-5-amino-4-oxopentanoate  as 
hydrochloride 
Levulan Kerastick® (not approved in 
Europe) 
20% aminolevulinic acid hydrochloride 
Magistral preparation  20% ALA gel/cream/emulsion 
PD P 506 A (not yet approved for clinical 
use) 
5-ALA released from Bandage 
BF-200 ALA (not yet approved for clinical 
use) 
5-ALA nanoemulsion 




- 88 - 
 
1.6.5.7. Factors influencing the efficiency of ALA-PDT  
Hua et al (1995) have investigated the mechanism(s) of ALA-based PDT in order to evaluate 
its relative effectiveness in controlling tumour growth in vivo. They have demonstrated that 
PPIX is the predominant porphyrin species formed in tumors after ALA administration. Thus 
ALA-PDT efficacy depends to a great degree on the rate of PPIX synthesis. Unfortunately, 
the great variability in PPIX biosynthesis poses limitations to this therapy. The response rates 
of ALA-PDT vary widely due to suboptimal production of PPIX, which limits the overall 
anticancer photochemical reactions and accounts for the differences in clinical responses 
(Gerritsen et al, 2009; Ickowicz et al, 2004). It appears that the differential expression levels 
of the rate-limiting enzymes in heme biosynthesis pathway between non-malignant and 
malignant cells, is the main factor affecting the accumulation of PPIX in those cells 
(Greenbaum et al, 2002). These key enzymes are ALAS, ALAD, PBGD and ferrochelatase. 
ALA supply circumvents the first enzyme ALAS, thus the synthesis rate is largely dependent 
on the other enzymes especially PGBD, ALAD and ferrochelatase as demonstrated in a series 
studies in the field (e.g. Grinblat et al, 2006; Ickowicz et al, 2004; Miyake et al, 2009; 
Feuerstein et al, 2009).  
The accumulation of PPIX in the cells is not only influenced by the ratio of ALA conversion 
to PPIX but is also related to the ferrochelatase-mediated insertion of ferrous iron into the 
porphyrin macrocycle to produce the heme molecule. It has been shown that differences in 
iron availability in cells may influence the patterns of PPIX accumulation in vivo (Licznerski 
et al, 1993). The selective accumulation of PPIX in some malignant cells is also attributed to 
their low ferrochelatase activity (Schoenfeld et al, 1988; El-Sharabasy et al, 1992). A 
correlation between cell proliferation rates and PPIX synthesis has also been suggested 
(Rebeiz et al, 1992; Malik et al, 1989), but these studies lack an explicitly stated proliferation 
rate. A clear model does not emerge from these studies, probably because of the difficulty in 
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comparing the results obtained from tumors of diverse origin, where the rate of PPIX 
accumulation is dictated by a varying combination of specific cellular and tissue 
characteristics. For the clinicians, standardized PDT protocols are needed; nevertheless, such 
protocols must be finely tuned for specific lesions depending on PPIX synthesis capacity in 
order to improve the clinical outcome. Therefore there is a strong requirement to find cell and 
tissue markers which will indicate which tumors are suitable for ALA/PDT, since the 
effectiveness of ALA in inducing PPIX in the cells is cell-, tissue- and organ-specific 
(Kennedy et al, 1990; Feuerstein et al, 2009). In 1995, Oseroff and coworkers (Rittenhouse-
Diakun et al, 1995) used the transferrin receptors (TfRs, also designated CD71) of the cells as 
a marker for the intracellular level of iron in ALA/PDT. They showed that some activated 
normal and malignant lymphocytes that have increased CD71 expression, can be identified as 
cells highly susceptible to ALA/PDT and therefore could serve as a PDT target. However this 
marker may have limited usefulness because in some malignant cell lines, the presence of 
elevated TfR expression is unrelated to internal iron stores (Neckers, 1991; Reelfs et al, 
2010).  
Direct measurement of intracellular levels of LI in tumour cells is extremely difficult. 
Pourzand and coworkers (1999b) have demonstrated that the sensitive estimation of 
intracellular level of LI as monitored by the level of activation of cytosolic IRP-1 could serve 
as potential sensitive marker for developing PDT protocols since it identifies cells and tissues 
with a propensity to accumulate PPIX and it is therefore likely to predict the effectiveness of 
such therapies (Pourzand et al, 1999b).  
Because of the clear role of iron in determining the efficiency of PPIX accumulation after 
ALA administration, iron chelator treatment combined with ALA-PDT has been proposed as 
an efficient mean to improve this therapy by decreasing the amount of available iron in the 
cells.  Preclinical studies have already shown that iron chelators such as EDTA, 
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Desferrioxamine mesylate (Desferal®, Novartis, Basel, Switzerland), 2-allyl-2-
isopropylacetamide and 1,10-phenanthroline have potential for increasing PPIX accumulation  
from ALA (Licznerski et al, 1993; Hanania and Malik, 1992; Iinuma et al, 1994, He et al, 
1993; Berg et al, 1996; Liu et al, 2004). However these chelators are highly hydrophilic and 
therefore are not suitable for topical application. Studies from MacRobert and Curnow 
laboratories have introduced CP94 (1,2-diethyl-3-hydroxypyridin-4-one hydrochloride) that 
appears to be a more suitable iron chelating agent for dermatological ALA-PDT.  CP94 
possesses not only high specificity for iron but also a lower molecular weight and higher 
lipophilicity than DFO and EDTA (Smith et al, 1997; Liu and Hider, 2002). The 
effectiveness of this chelator in enhancing the PPIX levels following ALA administration has 
been shown in in vitro cell culture studies as well as in in vivo animal models and skin 
explants (Bech et al, 1997; Casas et al, 1999; Chang et al, 1997; Curnow et al, 1998, Curnow 
et al, 2006; Pye and Curnow, 2007; Blake and Curnow, 2010). The use of lipophilic strong 
iron chelators such as CP94 in combination with ALA/MAL may circumvent the problems of 
unresponsiveness of deep dermatological lesions in topical ALA-PDT and should also 
improve the efficiency of ALA-PDT in skin tumours with low response to ALA-PDT. In a 
recent study, Pye et al (2008) demonstrated the improved efficiency of MAL-PDT of nodular 
BCC when combined with CP94. (Campbell et al, 2004)             
Although little information exists about the tissue penetration of ALA after topical 
application, the fluorescence of ALA-mediated PDT in normal and diseased human skin has 
been found to increase with time after topical ALA application, with a plateau of 
approximately 4-14 h, depending on ALA concentrations (2-40%) in formulations, amount of 
administration (30-50 mg/cm
2
), and application time (up to 24 h) used (Orenstein et al, 1995; 
Morton et al, 1995; Peng et al, 1997). In general, topical application of ALA alone for less 
than 4 h produces PPIX only at the site of ALA application, whereas the administration for a 
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longer period (up to 14 h) or combined with skin penetration enhancers (e.g. 
dimethylsulfoxide; DMSO) leads to a generalized photosensitization of the skin (Orenstein et 
al, 1995; Peng et al, 1997). Generally, ALA-induced PPIX fluorescence can not be detected 
in the skin 24 h after completion of topical ALA application. ALA itself does not seem to be 
toxic to tissues when concentrations <50% in water/oil emulsion by weight are topically 
applied for at least 48 h. Moreover, no evidence shows toxicity of ALA-mediated PPIX 
accumulation on tissues before light exposure (Peng et al, 1997). Cellular studies have 
demonstrated that ALA can be administered at very high concentrations without producing 
cytotoxic effects in the dark. At concentrations lower than 3 mM, no dark cytotoxic effects 
could be observed (e.g. Pourzand et al, 1999b; Berlanda et al, 2010). The intracellular 
production of PPIX is almost linear over the investigated incubation time (30h). PPIX formed 
from ALA is rapidly degraded, thus minimising the period of light sensitivity post PDT. 
Another advantage of ALA-induced PPIX is that it is only produced in living cells, which is 
beneficial for treatment of cells without production of ROS in surrounding extracellular 
matrix (Berlanda et al, 2010).    
 
1.6.5.8. Side effects of ALA- and MAL-PDT   
Topical ALA- or MAL-based PDT has considerably advanced the management of NMSC, 
providing a treatment option for AK, BCC and BD, with good clinical outcomes, low 
recurrence rates and enhanced cosmetic acceptability (Morton et al, 2002). However the most 
common and troublesome acute adverse event of topical PDT remains the burning or stinging 
pain that occurs during light exposure, and may continue post-exposure in a minority (Morton 
et al, 2002) Pain is restricted to the illuminated area and may reflect nerve stimulation and/or 
tissue damage by ROS, possibly aggravated by hyperthermia (Morton et al, 2002). Treatment 
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of psoriasis and viral warts in particular is frequently limited by pain (Schleyer et al, 2006). 
Pain appears more intense in large area lesions, with AK, BD and BCC covering an area of > 
130 mm
2
 significantly more painful to treat (Grapengisser et al, 2002, Sandberg et al, 2006). 
In particular, patients receiving PDT of AK in the face and scalp often experience severe pain 
during treatment (Grapengiesser et al, 2002; Sandberg et al, 2006). There is therefore an 
imminent risk that patients are unable to complete the treatment session or will refrain from 
treatment in the future. Untreated lesions may increase the risk of developing SCC in the long 
run (Anwar et al, 2004; Salsche 2000). As topical ALA/MAL-based PDT has good cure rates 
in the treatment of extensive AK and gives excellent cosmetic results, it is necessary to find 
new strategies to reduce the pain experience to an acceptable level.  
MAL may offer advantages over ALA in terms of its deeper skin penetration (up to 2 mm in 
depth) due to potentially enhanced lipophilicity and greater specificity for neoplastic cells 
(Peng et al, 2001). As ALA but not MAL is transported by γ-aminobutyric acid carriers, it 
has been speculated that MAL might provoke less nerve fibre stimulation and subsequent 
pain (Rud et al, 2000). The comparative PDT studies with topical ALA and its methyl ester 
derivative MAL are still ongoing. While some studies have demonstrated that pain was 
significantly higher in the ALA- than MAL-treated sites (both during and immediately after 
PDT), other studies have indicated that pain was greater in MAL-treated sites with more 
intense PPIX fluorescence and also with higher fluence rates with 20% of patients unable to 
complete the treatment due to unbearable pain (Wiegell et al, 2003, 2006 and 2008; Kasche 
et al, 2006; Kuipers et al, 2006; Moloney et al, 2007). More comparative studies are 
necessary to elucidate the pain associated with either compounds, as the high inter-subject 
variability within small subject group studies potentially obscure any existing relationship.  
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The degree of pain has also been related to intensity of light delivery; fractionated light doses 
increase tolerance of the procedure and may at the same time increase cure rates (Ericson et 
al, 2004; Babilas et al, 2007).  
A range of techniques has been used in an attempt to reduce topical ALA/MAL-PDT-related 
pain, including local anesthesia and cooling the skin with fans or sprayed water (Halldin et al, 
2009) Cold-water spray is used as pain relief routinely but is deficient when treating large 
areas such as the forehead and scalp. The difficulty in finding a pain relieving strategy has 
been shown in earlier studies, e.g. three studies have shown the inefficacy of topical 
anesthesia such as tetracaine gel, a mixture of lignocaine 2.5% and prilocaine 2.5%, or 
morphine gel 0.3% (Holmes et al, 2004; Langan and Colins, 2006; Skiveren et al, 2006). 
Blowing cold air (-35
o
C) on the treatment area during PDT also seems to fail to reduce the 
pain significantly (Pagliaro et al, 2004). Transcutaneous electrical nerve stimulation has been 
tried as pain reducing method but had limited effect. Subcutaneous infiltration anesthesia has 
been used during PDT of extensive AK of the cheek. The pain decreased but this type of 
anesthesia is not possible to use on the forehead and scalp. Applying local anesthesia to such 
areas is also inappropriate due to large number of painful injections needed. Nerve blocks 
have also been used to provide effective pain relief during PDT for extensive AK in the face 
(Paoli et al, 2008). A recent study has combined the benefits of supraorbital and supraocular 
nerve blocks of the latter study with nerve blocks of the greater and lesser occipital nerves to 
anesthetize both the forehead and scalp in order to alleviate pain during PDT in these areas. 
However in both studies intervariability was observed between the patients, emphasizing the 
need for individual considerations to find the most adequate pain relieving method for each 
patient.    
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1.7. Aims and objectives of the study 
The present proposal responds to the urgent need of finding alternative efficient and more 
tolerable methods for topical ALA-based PDT of skin lesions such as AK. While the topical 
ALA- and MAL-based PDT of AK with prolonged visible or red light treatment provides 
efficient result and cosmetic outcome, discomfort from PDT is still a considerable hindrance 
with up to 20% of patients reporting pain as being „severe‟ and „intolerable‟. This often 
results on patients‟ reluctance to this therapy, putting them at risk of developing SCC. Further 
optimization of the treatment protocol including light source, dose and duration therefore 
seems crucial to try and alleviate pain. In the present project, we hypothesized that the 
damaging effects of rapid release of labile iron by short pulses of low UVA doses following 
ALA-treatment may be exploited to provide a rapid mean to improve the effectiveness of 
ALA-PDT of skin lesions while reducing considerably the therapy time and the 
discomfort/pain associated with other light treatments such as prolonged high intensity 
visible light treatment. We therefore evaluated the response of spontaneously immortalized 
HaCaT keratinocytes to either single or two short pulses of UVA with 1h interval by 
evaluating the level of cell survival with the MTT viability assay and the mode of cell death 
with the dual Annexin V/propidium iodide flow cytometric assay. To ascertain that the 
cytotoxic effects observed were iron-dependent, we also evaluated the response of HaCaT 
cells that were iron-loaded prior to ALA-UVA split dose treatment. Our ultimate goal was to 
demonstrate that applying split low doses of UVA radiation in combination with ALA may 
be an effective intervention strategy to decrease considerably the time of light treatment and 
therefore reduce the pain associated with prolonged conventional topical ALA-PDT of skin 
lesions such as AK.  
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CHAPTER TWO 
                        MATERIALS AND METHODS 
 
2.1. Chemicals 
All the reagents were purchased from Sigma-Aldrich Chemical Co. (Poole, UK) unless 
otherwise specified. All the cell culture materials were obtained from Life Sciences 
Technologies (Paisley, UK), except the fetal calf serum (FCS), which was obtained from 
PAA (Austria),  Dulbeco‟s Minimum Essential Medium (DMEM) that was supplied by 
Gibco BRL Invitrogen Corporation (Life Technologies, UK) and Annexin-V-FITC that was 
purchased from Roche (UK). MilliQ water used to prepare phosphate buffered saline (PBS) 
and other stock solutions were issued from a Millipore purification system (MilliQ cartridge: 
Millipore, Bedford, MA) in order to minimize the presence of trace elements such as 
transition metals. 
 
2.2. Cell Culture 
2.2.1. Cell model  
The cell model used in this study was the spontaneously immortalized human skin 
keratinocyte cell line HaCaT that was originally derived from an adult back in Boukamp‟s 
laboratory (Boukamp et al, 1988). This cell line maintains full epidermal differentiation 
capacity but remains non-tumorigenic (Boukamp et al, 1988). Cell culture procedures were 
conducted in a flow hood, (M.D.H, InterMed) using aseptic technique. 
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2.2.2. Preparation of media 
The medium employed was 10% FCS-DMEM (high glucose Dulbecco‟s modified Eagle‟s 
medium) containing 0.25% sodium bicarbonate, 2 mM L-glutamine, and 50 IU/ml of each of 








Cells were trypsinised once or twice a week and seeded back into T125 cm
2
 flasks, so they 
were always in the exponential phase and at the required confluency of 70-80%. 
For trypsinisation, the medium was removed and retained in a separate tube. The adherent 
cells were then washed with PBS buffer and incubated with 2 ml of 0.25% trypsin at 37
o
C 
under 5% CO2, until detached (usually 5-10 min). Retained media was then added back to the 
flask in order to inactivate the trypsin. Next, the cells were centrifuged for 5 min at 1200 rpm 
in the Jouan B3.11 centrifuge. After removing the supernatant the cell pellet was resuspended 
in fresh 10% FCS-DMEM medium and cells were counted under a light microscope i.e. A 
small aliquot of the cell suspension was mixed with Trypan blue dye and then counted under 
microscope using a Neubauer-improved haemocytometer (Marienfeld, Germany). The cells 
were then diluted with fresh medium at the required density and incubated at 37
o
C under 5% 
CO2.  
2.2.4. Experimental set up 
For experiments, 8.4 x 10
4 
cells were seeded in 3 cm plates and grown for 3 nights at 37ºC 
incubator under 5% CO2 to reach 80% confluency. For accuracy, three 3 cm plates were used 
for each experimental condition.  
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2.3 Treatments 
2.3.1. UVA irradiation 
2.3.1.1. UVA lamp  
The broad spectrum 4 kW lamp (Sellas, Germany) emits primarily UVA irradiation 
(significant emission in the range of 350-400 nm) and some near visible radiation longer than 
400 nm. Figure 2.1 illustrates the spectrum of the lamp. This lamp is suitable for ALA-PDT 
studies, as the absorption spectrum of PPIX is known to have a peak around 405-410 nm. 
Excitation at this wavelength produces an intense red emission with its maximum at 635 nm 
(Ericson et al, 2003). Furthermore blue light has been shown to be more potent than red light 
in activating PPIX (Peng et al, 1997). 
The preliminary data from this laboratory have previously indicated that a 2h treatment with 
ALA concentration of 0.5 mM could significantly sensitise the HaCaT keratinocytes to the 
damaging effects of UVA (unpublished data, Pourzand‟s laboratory, personal 
communication).  
2.3.1.2. UVA doses  
The UVA doses employed were 5, 10, 20 and 50 kJ/m
2
. Typically with a fluence rate of 150 
W/cm
2
 and a distance of 30 cm, the irradiation time was between 12 seconds to 2 min for all 
the doses used. At natural sunlight exposure level, these doses would be between 1.5 to 15 
min at sea level (Pourzand et al, 1999). The higher doses of 20 and 50 kJ/m
2
 would be more 
relevant for skin therapeutic purposes. This is because of the attenuation of the applied UVA 
dose by passage through the outer skin layers. The UVA doses were measured using an 
IL1700 radiometer (International light, Newbury, MA).  





Figure 2.1. Emission spectrum from the Sellas 4kW UVA lamp 
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2.3.1.3 Irradiation procedure 
Irradiation was carried out in a light-controlled air-conditioned room at 18ºC in order to 
maintain the temperature of the cells to approximately 25ºC throughout the radiation 
procedure. Prior to irradiation, cells were washed with PBS, followed by addition of PBS 




to the cells in 3 cm plates to maintain cell membrane 
integrity. The cells were then irradiated with UVA doses of 5, 10, 20 or 50 kJ/m
2
. After 
irradiation, cells were incubated in conditioned medium (the retained medium in which the 
cells had been grown) prior to MTT or flow cytometry analyses. For split dose experiments, 
following the first irradiation cells were incubated for one hour in conditioned media under 
dark conditions at 37
o
C and then re-irradiated (or not), with UVA-doses of 5, 10, 20 and 50 
kJ/m
2 




. For ALA treated cells, cells were kept under 
dark condition prior to irradiation and tehn split dose irradiations, during the 1 h dark 
interval. The control samples were treated in the same manner except that they were not 
irradiated (i.e. kept in dark).                                       
2.3.2. ALA treatment 
ALA stock solution: 100 mM in H2O 
Chemical name: 5-aminolaevulinic acid hydrochloride. 
Treatment: Cells were incubated with 0.5 mM ALA for 2 h (as previously established in this 
laboratory, Pourzand et al, 1990b) in 1% FCS DMEM at 37
o
C under dark conditions prior to 
irradiation.   
2.3.3. Hemin treatment 
Hemin stock solution: 20 mM hemin in dimethyl sulfoxide (DMSO) 
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Chemical name: Hemin chloride. 
Treatment: Cells were treated with hemin (at a final concentration 10 µM as previously 
established in this laboratory for the purpose of this study., Zhong, PhD thesis, 2000) for 18h 
at 37ºC (5% CO2) under dark conditions. 
 
2.4. MTT Assay 
2.4.1. Principle of the assay 
Cellular dehydrogenase enzyme converts MTT [3-(4, 5-dimethylthiazol-2-ye)-2, 5-diphenyl 
tetrazolium bromide], a yellow water-soluble substrate, into a dark blue formazan product 
that is insoluble in water. The amount of formazan produced is directly proportional to 
cellular reductive capacity and subsequently cell viability. So the MTT colorimetric assay 
(Mosmann, 1984; Berridge et al, 1996) can be used as a cell viability assay.  
 
2.4.2. MTT stock solution 
The MTT stock solution was prepared at a final concentration of 5 mg/ml in PBS. The 
solution was then filtered through a 0.22 m filter for sterilization and stored in small 
aliquots at -20ºC.  
2.4.3. Procedure 
On the day of the experiment, MTT stock solution was first diluted in serum-free DMEM 
medium (SFM) to the final concentration of 0.5 mg/ml (i.e. MTT/SFM solution). In UVA-
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based experiments, following UVA irradiation, the cells were first incubated for 30 min in 
conditioned media to recover. Then the conditioned media was replaced by MTT/SFM 
solution. Typically, 0.5 ml of MTT/SFM was added into each 3 cm plate and the cells were 
then incubated for 3h at 37ºC in the CO2 incubator under dark conditions.  The MTT/SFM 
solution was then aspirated and 0.5 ml DMSO was added to each well. The plates were then 
swirled for 3 min on a 3D rocking platform (Stuart Scientific, UK). A small aliquot (i.e. 
usually 100 l) was transferred from each plate to a 96 well plate and read by Dynatech plate 
reader MR-5000 (Dynatech, Guernsey, Channel Islands) at 570 nm using DMSO as a blank 
control. The results were expressed as percentage cell viability of relevant controls. 
 











Figure 2.2: Experimental outline for UVA-ALA PDT single and split dose   
                               strategies (+/- hemin). 
- 102 - 
 
2.5. Flow Cytometry 
2.5.1. Principle of the assay 
Quantification of apoptosis, by Annexin V-Fluorescein isothiocyanate (FITC) staining, and 
necrosis, by propidium iodide (PI) uptake, was evaluated by flow cytometry. In the early 
stages of apoptosis, phosphatidylserine (PS) translocates from the inner part of the plasma 
membrane to the outer layer. Annexin-V is a phospholipid-binding protein with a high 
affinity for PS. Identification of cell surface PS with Annexin-V serves as a marker for 
apoptotic cells. On the other hand necrotic cells that lose cell membrane integrity are stained 
with both PI and Annexin-V. Thus, Annexin-V and PI double staining can differentiate 
between necrotic and apoptotic cells (Zhong et al, 2004). In the present study, this assay was 
used to back up some of the key data obtained with the MTT assay. Figure 2.2 provides the 
summary of various treatments used prior to flow cytometry assay. 
 
2.5.2. Procedure 
Following the various treatments, cells were washed with PBS and incubated in incubation 
buffer (10 mM Hepes / NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl2) containing Annexin-V 
(20 µl/ml) and PI (20 µl/ml) for 15 min. Double stained cells were counted as necrotic 
whereas Annexin-V positive, PI negative cells were scored as apoptotic. A minimum of 
10,000 cells were analyzed per sample on a BD FACSCanto™ flow cytometer (Becton 
Dickinson, Erembodegen, Belgium). The following settings were used for the analyzed cell 
line (HaCaT): FL1 (530 +/- 15 nm) in log data collection and FL3 in log data collection. Two 
dimensional dot plots were used to analyse the data of FL3 versus FL1 fluorescent profiles. 
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CellQuest software (Becton-Dickinson, Eremdodegem, Belgium) was used to analyse the 
data with a dual parameter of FL1 (Annexin-V) and FL3 (PI). 
 
2.6. Statistical analysis 
Results are expressed as mean +/- standard deviation (SD). Data were analysed using paired 
t-tests. The p value of less than 0.05 was considered to be significantly different between 
















The use of UVA radiation for ALA-PDT of superficial skin lesions such as AK may be 
advantageous as UVA is more damaging than visible light. Indeed UVA radiation is a strong 
oxidizing agent that generates ROS in exposed cells. Previous studies from this laboratory 
have highlighted that in addition to ROS, UVA exposure also promotes an immediate 
increase in the intracellular level of LI in skin cells that acts as a catalyst to produce more 
harmful ROS which readily damage the cellular compartments, leading to cell death 
(Pourzand et al, 1999; Zhong et al, 2004; Reelfs et al, 2010). The UVA-induced LI release is 
a major factor in inducing damage to skin because the excess LI persists up to 2h after 
irradiation due to lack of storage as a result of UVA-mediated degradation of the iron storage 
protein, Ft. The presence of potentially harmful LI within the early hours after UVA 
irradiation has been shown to further exacerbate the peroxidative skin damage leading to 
necrotic cell death, since the excess LI can not be safely sequestered in Ft (Zhong et al, 2004; 
Reelfs et al, 2004; Yiakouvaki et al, 2006; Reelfs et al, 2010). This property of UVA could 
potentially be exploited advantageously to improve the efficiency of ALA-PDT of skin 
lesions such as AK. Indeed by using UVA as the light source and by fractionating the dose 
applied into two short pulses with 1h interval, the ALA-treated lesions could be further 
sensitized to UVA-induced damage since the first dose of UVA would trigger the formation 
of ROS and extensive release of LI which in turn would intensify the damage caused by the 
second challenge dose of UVA.  
- 105 - 
 
In the present study, we evaluated the response of spontaneously immortalized HaCaT 
keratinocytes to either single or two short pulses of UVA with a 1 h interval. The level of cell 
survival following various conditions was evaluated with the MTT viability assay. The key 
data were further verified by dual Annexin V/propidium iodide assay by flow cytometry.   
 
3.2. The effect of ALA on HaCaT cell survival following 
irradiation with single doses of UVA 
The preliminary data from this laboratory have previously indicated that a 2h treatment with 
ALA concentration of 0.5 mM could significantly sensitise the HaCaT keratinocytes to the 
damaging effects of UVA (unpublished data, Pourzand‟s laboratory, personal 
communication). To confirm these data and to evaluate the range of low doses of UVA that 
may be suitable for the present project, the HaCaT cells were treated with 0.5 mM ALA for 2 
h and then exposed to a range of low doses of UVA (i.e. 5, 10, 20 and 50 kJ/m
2
). The MTT 
analysis was performed 24 h after irradiation. The results (Figure 3.1) revealed that in 
absence of ALA, low doses of UVA had no significant effect on cell viability when compared 
to untreated controls. However ALA treatment substantially increased the susceptibility of 
HaCaT cells to UVA-induced damage as upon UVA exposure, the percentage of cell viability 
in ALA-treated cells significantly decreased when compared to unirradiated controls.        
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Figure 3.1. Effect of ALA on cell viability 24h after irradiation of cells with single doses of UVA. 
HaCaT cells were treated with 0.5 mM ALA for 2h at 37ºC under dark condition prior to irradiation with single 
UVA doses of 5, 10, 20 or 50 kJ/m
2
. Control cells were treated the same except that they were either not 
irradiated (i.e. 0) and (or) not treated with ALA (i.e. grey columns). 
MTT analysis was performed 24h after irradiation. The results were expressed as mean + standard deviation 
(n=3-17). 
*: p<0.05, significantly different from the unirradiated ALA-treated cells. 




†:  p<0.05, significantly different from the ALA-treated cells irradiated with single dose of 20/0 kJ/m2.
 
 
To confirm the results obtained with MTT, the level of apoptotic and necrotic cell death was 
scored by flow cytometry using the dual Annexin V/PI staining method. For this purpose, the 
ALA-treated cells were exposed to UVA doses of 10 or 50 kJ/m
2
 and then incubated for 24 h 
at 37
o
C prior to analysis by flow cytometry. Figure 3.2 is a representative example of such an 
analysis. The flow cytometry analysis showed residual apoptotic cells in some of the 
conditions used in this study. This is in agreement with previous findings from this laboratory 
showing that apoptosis in not the primary mode of cell death in HaCaT cells using these 
dosing parameters (Zhong et al, 2004).  Indeed in control cells and in cells irradiated with 
§ 
§ 
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UVA alone or ALA alone, a low percentage of necrotic cell death was observed. But most 
importantly, ALA-treatment combined with UVA irradiation caused a dose-dependent 
increase in the percentage of necrotic cell death in HaCaT cells. The observed dose-
dependent increase in necrotic cell death in combined ALA+UVA-treated cells in the flow 
cytometry analysis correlated with a reciprocal decrease in percentage of cell viability of the 
same conditions in MTT assay.  
Taken together, the flow cytometry analysis was in agreement with the MTT analysis, as both 
assays confirmed that ALA-treatment strongly sensitises the HaCaT cells to UVA-induced 
cell damage and death. Furthermore, it was apparent that necrosis is the primary mode of cell 
death induced by UVA in ALA-treated cells. 
Figure 3.2. The effect of ALA treatment on the percentage of necrosis and apoptosis in HaCaT 
cells 24h following UVA irradiation. HaCaT cells were treated with 0.5 mM ALA for 2h at 37ºC under 
dark condition prior to irradiation with single doses of 10 or 50 kJ/m
2
.  Control cells were treated the same 
except that they were either not irradiated and (or) not treated with ALA. Flow cytometry analysis was 
performed 24h after the UVA irradiation following Annexin V-PI staining. „C‟ refers to the untreated control; 
„HU‟ is a positive control for necrosis where HaCaTcells treated with 20 µM hemin for 18h were irradiated with 
a UVA dose of 250 kJ/m
2; „ALA‟ refers to the cells treated with ALA alone; „UVA10‟ and „UVA50‟ refer to 
cells irradiated with UVA single doses of 10 and 50 kJ/m
2
, respectively; „ALA+UVA10‟ and „ALA+UV50‟ 
refer to ALA-treated cells irradiated with UVA single doses of 10 and 50 kJ/m
2
, respectively. (n=2) 
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3.3. The effect of ALA on HaCaT cell survival following 
irradiation with a second dose of UVA 
To determine whether a second challenge dose of UVA 1h following the first irradiation 
could further exacerbate the UVA-mediated cell damage of ALA-treated HaCaT cells, a 
series of UVA split-dose combination experiments were designed where cells were subjected 
to two short pulses of UVA with 1 h interval.  To this regard, the ALA-treated HaCaT cells 
were first irradiated with a single dose of 5, 10, 20 or 50 kJ/m
2
 UVA and then subjected to a 
second dose of 5, 10, 20 or 50 kJ/m
2
, 1h following the first UVA radiation.  The MTT 
viability assay was performed 24 h following the second UVA irradiation.  
 
Figure 3.3 shows the summary of the first set of UVA split dose combination experiments 
using a second UVA dose of 5 kJ/m
2
. As it can be seen, while a low single UVA dose of 5 
kJ/m
2
 only marginally decreased the cell viability of ALA-treated HaCaT cells, a second dose 
of the same intensity significantly decreased the ALA-treated cells‟ viability to 54.7% when 
compared to untreated control. Similarly, a second dose of 5 kJ/m
2
 significantly decreased the 
viability of ALA-treated cells irradiated with an initial dose of 10 kJ/m
2
 from 57% to 12%.  
Furthermore, in ALA-treated cells irradiated with initial higher UVA doses of 20 or 50 kJ/m
2
, 
the second dose of 5 kJ/m
2
 also provided additional significant cell killing, when compared to 
ALA-treated cells irradiated with the corresponding single doses.  
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Figure 3.3. The effect of ALA on cell viability 24 h after the irradiation of cells with single or 
double split doses of UVA. HaCaT cells were first treated with 0.5 mM ALA for 2 h at 37ºC under dark 
condition prior to irradiation with a single dose of 0, 5, 10, 20 or 50 kJ/m
2
 (indicated as 5/0, 10/0, 20/0 and 50/0 
respectively). For split-dose conditions, following the first irradiation cells were incubated for 1h in conditioned 
media and then exposed to a second UVA dose of 5 kJ/m
2
 (indicated as 5/5, 10/5, 20/5 and 50/5 respectively). 
All control cells were treated the same except that they were either not irradiated (i.e. 0/0) and (or) not treated 
with ALA. MTT analysis was performed 24 h after the second irradiation.   
The results were expressed as mean ± standard deviation (n=3-17). 
§: p<0.05, significantly different from the ALA treated cells irradiated with UVA single dose of 5/0 kJ/m
2
.  
†: p<0.05, significantly different from the ALA treated cells irradiated with UVA single dose of 10/0 kJ/m2 
‡: p<0.05, significantly different from the ALA treated cells irradiated with UVA double dose of 5/5 kJ/m2 
 
Figure 3.4 shows the summary of the second set of UVA split dose combination experiments 
using a second UVA dose of 10 kJ/m
2
. As it can be seen, compared to single dose treatment 
(i.e. 10/0 +ALA), a second UVA dose of 10 kJ/m
2
 significantly decreased the cell viability of 
ALA-treated cells pre-irradiated with a UVA dose of 10 kJ/m
2
 (i.e. from 57.1 + 7.4 to 17.1+ 
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triggered additional decrease in cell viability in ALA-treated cells pre-irradiated with a 
moderate dose of 20 kJ/m
2
. Finally, in this set of split-dose combination, the „50/10+ALA‟ 
condition provided the most efficient decrease in percentage cell viability that was not only 
significantly lower than all the ALA-treated cells irradiated with single UVA dose but was 
also lower than the ALA-treated „10/10‟ double-dose combination. Also a significant 
decrease was observed in the control cells irradiated with double UVA dose of 50/10 in 








Figure 3.4. Effect of ALA on cell viability 24h after the irradiation of cells with single or double 
dose of UVA. HaCaT cells were first treated with 0.5 mM ALA for 2h at 37ºC under dark condition prior to 
irradiation with a single dose of 0, 10, 20 or 50 kJ/m
2
 (indicated as 10/0, 20/0 and 50/0 respectively). For double 
dose conditions, following the first irradiation cells were incubated for 1h in conditioned media and then 
exposed to a second UVA dose of 10 kJ/m
2
 (indicated as 10/10, 20/10 and 50/10 respectively). All control cells 
were treated the same except that they were either not irradiated (i.e. 0/0) and (or) not treated with ALA. The 
MTT analysis was performed 24h after the second irradiation. The results were expressed as mean ± standard 
deviation (n=3-17).  
¥: p<0.05, significantly different from the ALA treated cells irradiated with UVA single dose of 10/0 kJ/m
2
. 
†: p<0.05, significantly different from the ALA treated cells irradiated with UVA single dose of 20/0 kJ/m2. 
‡: p<0.05, significantly different from the ALA treated cells irradiated with UVA single dose of 50/0 kJ/m2. 
µ: p<0.05, significantly different from the ALA treated cells irradiated with double UVA dose of 10/10 kJ/m
2
. 
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To confirm the effect of split-dose UVA treatments in improving the efficiency of cell killing 
of ALA-treated HaCaT cells, the level of apoptotic and necrotic cell death was scored by 
flow cytometry using the dual Annexin V/PI staining method. For this purpose, the ALA-
treated cells were exposed either to single or double split-dose of 10 kJ/m
2
 UVA with 1h 
interval and then incubated for 24h at 37
o
C prior to analysis by flow cytometry. As it can be 
seen in Figure 3.5, compared to single dose treatment (ALA+UVA10), a second UVA dose 
of 10 kJ/m
2
 1h following the initial dose, increased the percentage of necrotic cell death in 
ALA-treated cells (i.e. from 17% in „ALA+UVA10‟ to 50% in „ALA+UVA10+UVA10‟ 
condition). However in the control groups (i.e. in „C‟ and „ALA‟) and in cells irradiated with 
UVA alone (i.e. „UVA10‟), the percentage of necrotic cell death remained very low. The 
observed increase in necrotic cell death in „ALA+UVA10+UVA10‟ condition in flow 
cytometry analysis correlated with a reciprocal decrease in percentage cell viability of the 
same condition in MTT assay.  
 
Taken together, the flow cytometry analysis was in agreement with the MTT analysis, as both 
assays confirmed that two short pulses of UVA with 1h interval further sensitises the ALA-
treated HaCaT cells to UVA-induced cell damage and death. Furthermore it was again 
apparent that necrosis is the primary mode of cell death induced by UVA in ALA-treated 
cells. 
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Figure 3.5. The effect of ALA on the percentage of necrosis and apoptosis 24 h after irradiation 
of cells with single or double split doses of UVA. HaCaT cells were first treated with 0.5 mM ALA for 2 
h at 37ºC under dark condition prior to irradiation with a single dose of 10 kJ/m
2
 (indicated as „ALA+UVA10‟). 
For split dose conditions, following the first irradiation cells were incubated for 1h in conditioned media and 
then exposed to a second UVA dose of 10 kJ/m
2
 (shown as ALA+UVA10+UVA10). All control cells were 
treated the same except that they were either not irradiated (i.e. „C‟ and „ALA‟) and (or) not treated with ALA 
(i.e. „UVA10‟ and „UVA10+UVA10‟). „HU‟ is a positive control for necrosis where HaCaTcells pre-treated 
with 20 µM hemin for 18 h were irradiated with a UVA dose of 250 kJ/m
2
. Flow cytometry analysis was 
performed 24 h after the UVA irradiation following Annexin-V+PI staining.  
 
 
Figure 3.6 shows the summary of the third set of UVA split dose combination experiments 
using a second UVA dose of 20 or 50 kJ/m
2
. As it can be seen, the percentage cell viability in 
ALA-treated cells irradiated with two split-dose of 20 or 50 kJ/m
2
 was significantly lower 
than ALA-treated cells irradiated with the corresponding single UVA doses. Interestingly in 
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ALA-treated cells, the decrease in percentage cell viability of cells with double UVA dose 
combination of „50/20‟ kJ/m2 was similar to that „50 /50‟ kJ/m2 (n = 2). 
Figure 3.6. Effect of ALA on cell viability 24 h after the irradiation of cells with single or double 
dose of UVA. HaCaT cells were first treated with 0.5 mM ALA for 2 h at 37ºC under dark condition prior to 
irradiation with a single dose of 20 or 50 kJ/m
2
 (indicated as 20/0 and 50/0, respectively). For double dose 
conditions, cells were incubated for 1 h in conditioned media before irradiation with second doses of 20 and 50 
kJ/m
2
 (shown as 20/20, 50/20 and 50/50 respectively). All control cells were treated the same except that they 
were either not irradiated (i.e. 0/0) and (or) not treated with ALA. MTT analysis was performed 24 h after the 
second  irradiation. The results were expressed as mean ± standard deviation (n=3-17). 
*: p<0.05, significantly different from the ALA treated cells irradiated with UVA single dose of 20/0 kJ/m
2
. 
†: p<0.05, significantly different from the ALA treated cells irradiated with UVA single dose of 50/0 kJ/m2. 
 
Figure 3.7 shows the summary of the fourth set of UVA split dose combination experiments 
using a first UVA dose of 5 kJ/m
2
. As it can be seen, the combination of low first dose of 
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experiment and was no better than a single dose of ALA +20 kJ/m
2
 UVA unless a second 
UVA dose of 50 kJ/m
2
 was employed. This is presumably because the first low UVA insult 
does not provide enough impact in terms of radiation-induced ROS production and LI release 
to influence the extent of damage caused by second irradiation and as a result even higher 
second doses of UVA fails to provide the desired cumulative cell damage. These results also 
demonstrate that when ALA-treated cells are initially irradiated with a low dose of 5 kJ/m
2
, 
the second UVA dose challenge of 5, 10 or 20 kJ/m
2
 fails to provide a dose-response. 
Furthermore no significant difference in cell viability could be observed between ALA-
treated cells irradiated with single UVA doses of 20 and 50 kJ/m
2
 and ALA-treated double 
UVA dose combination of „5/20‟ and „5/50‟ kJ/m2. Nevertheless the double-dose 
combinations of 5/5 and 5/10 kJ/m
2
 significantly decreased the viability of ALA-treated cells 
when compared to ALA-treated cells irradiated with single dose of 5 or 10 kJ/m
2
. Overall, in 
comparison with previous sets of combination, the results of Figure 3.7 strongly suggest that 
using such a low initial dose of UVA is not an efficient approach to improve the efficiency of 
cell killing with UVA split-dose ALA-PDT.  
 
Based on these experiments, it was concluded that the third UVA split dose combination (i.e. 
results illustrated in Figure 3.6) provide the most promising approach to improve the 
efficiency of cell killing of ALA-treated HaCaT cells, since the initial UVA insult appears to 








Figure 3.7. Effect of ALA on cell viability 24h after the irradiation of cells with single or double dose of 
UVA. HaCaT cells were first treated with 0.5 mM ALA for 2h at 37ºC under dark condition prior to irradiation 
with a single dose of 0, 5, 10, 20 or 50 kJ/m
2
 (indicated as 5/0, 10/0, 20/0 and 50/0). For double dose conditions, 
following the first irradiation, cells were incubated for 1h in conditioned media and then exposed to second 
UVA doses of 5, 10, 20 or 50 kJ/m
2
 (shown as 5/5, 5/10, 5/20 and 5/50 respectively). All control cells were 
treated the same except that they were either not irradiated (i.e. 0/0) and (or) not treated with ALA. MTT 
analysis was performed 24h after the irradiation. The results were expressed as mean ± standard deviation (n=3-
17). 
§: p<0.05, significantly different from the ALA treated cells irradiated with UVA single dose of 5/0 kJ/m
2
. 
          
¥: p<0.05, significantly different from the ALA treated cells irradiated with UVA single dose of 10/0 kJ/m
2
. 
          
†: p<0.05, significantly different from the ALA treated cells irradiated with UVA single dose of 20/0 kJ/m2. 
          
µ: p<0.05, significantly different from the ALA treated cells irradiated with UVA double dose of 5/5 kJ/m
2
. 
          
‡: p<0.05, significantly different from the ALA treated cells irradiated with UVA double dose of 5/10 kJ/m2. 
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3.4. The effect of hemin and ALA on HaCaT cell survival 
following irradiation with single or double split-doses of UVA 
Previous data from this laboratory have demonstrated that Ft iron is the major source of LI 
release that is observed immediately following the radiation insult (Pourzand et al, 1999; 
Zhong et al, 2004; Reelfs et al, 2010). Indeed preventing the UVA-mediated Ft degradation 
by specific protease inhibitors substantially decreased the UVA-induced increase in LIP 
(Pourzand et al, 1999). Studies by Zhong et al (2004) further demonstrated that iron loading 
of cultured skin fibroblasts and keratinocytes with overnight hemin treatment (i.e. 10-20 µM) 
can lead to a 4-5 fold increase in the intracellular level of Ft that could in turn cause a 
massive increase in LI (i.e. 3-4 fold increase) following UVA irradiation. The higher UVA-
induced LI release following hemin treatment strongly sensitises the skin keratinocyte cells to 
UVA-induced oxidative damage leading to early necrotic cell death 4 h following radiation 
insult (Zhong et al, 2004;  Reelfs et al, 2010).   
To determine the critical role of UVA-induced LI release in exacerbating the UVA-induced 
damage in ALA-treated cells, HaCaT cells were first treated for 18 h with the previously 
established concentration of 10 µM  hemin (Zhong, 2002) and then subjected to UVA doses 
of 5, 10 and 20 kJ/m
2
 following a 2 h treatment with ALA. The MTT analysis was performed 
4 h following the UVA irradiation. The results (Figure 3.8) demonstrated that hemin 
treatment per se or combined with UVA doses of 5-20 kJ/m
2
 had no significant effect on 
HaCaT cells‟ viability. Furthermore the sensitivity of ALA-treated cells to UVA was less 
apparent with a light dose of 5 kJ/m
2
. Nevertheless hemin treatment strongly sensitised the 
ALA-treated cells to UVA doses of 10 and 20 kJ/m
2
 in a dose-dependent manner.  These 
results are in agreement with previous findings from Zhong et al (2004) and are consistent 
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with the notion that increasing UVA-induced iron release by hemin treatment exacerbates the 
damaging effect of UVA in photosensitised ALA-treated cells.  
The low UVA dose of 5 kJ/m
2
 failed to show significant damage in hemin+ALA treated 
cells, presumably because this dose was not high enough to promote the breakdown of highly 
accumulated Ft molecules and to release their potentially harmful LI. 
 
  
Fig 3.8. Effect of ALA and (or) hemin on cell viability 4h after irradiation of cells with single 
doses of UVA. HaCaT cells were first treated (or not) with 10 µM hemin for 18h and then incubated (or not) 
with 0.5 mM ALA for 2h at 37
o
C under dark condition prior to irradiation with UVA doses 5, 10, or 10 kJ/m
2
. 
All control cells were treated the same except that they were either not irradiated and (or) not treated with ALA 
and hemin. MTT analysis was performed 4h after UVA irradiation. The results were expressed as mean ± 
standard deviation (n=3-5). 
*: p<0.05, significantly different from the unirradiated ALA-treated cells.     
§: p<0.05, significantly different from the corresponding irradiated ALA-treated cells.  
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 To confirm the effect of hemin treatment observed in Figure 3.8 with MTT, the level of 
apoptotic and necrotic cell death was scored by flow cytometry using the dual Annexin V/PI 
staining method 4 h following irradiation with a UVA dose of 10 kJ/m
2
. As it can be seen in 
Figure 3.9, compared to cells treated with ALA alone, hemin pre-treatment provoked 
substantial necrotic cell death in ALA-treated HaCaT cells even at this early time point after 
irradiation. These results are in agreement with MTT assay and are consistent with the notion 
that increasing UVA-induced LI release by hemin treatment strongly sensitises the ALA-
treated cells to iron-mediated oxidative cell killing. Furthermore it was again apparent that 
necrosis is the primary mode of cell death induced by UVA in hemin +/-ALA-treated cells 
using these particular dosing parameters.  
 
  
Figure 3.9. The effect of hemin and ALA treatments on the percentage of necrosis and apoptosis in 
HaCaT cell line. HaCaT cells were first treated (or not) with 10 µM hemin for 18 h and then incubated (or not) 
for 2 h with 0.5 mM ALA at 37
o
C under dark condition prior to irradiation with a single UVA dose of 10 kJ/m
2
. 
All control cells were treated the same except that they were either not irradiated and (or) not treated with ALA 







- 119 - 
 
To evaluate whether hemin treatment could also exacerbate the effect of second dose 
challenge of UVA in ALA-treated cells, the hemin+ALA-treated HaCaT cells were irradiated 
either with single UVA doses of 5 or 10 kJ/m
2
 or with a double UVA dose combination of 10 
and 5 kJ/m
2
 with a 1 h interval. The MTT analysis was performed 4h following irradiation.  
The results (Figure 3.10) demonstrated that compared to hemin+ALA-treated cells irradiated 
with single UVA doses of 5 and 10kJ/m
2
, the viability of hemin+ALA-treated cells further 
decreases following a second low UVA dose of 5kJ/m
2
. 
Overall, these results suggested that iron loading of cells with hemin prior to ALA+UVA 
treatment can not only increase the susceptibility of ALA-treated cells to low single doses of 
UVA but also could exacerbate the damage caused by an extremely low second dose of 
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Figure 3.10. Effect of hemin on cell viability of ALA-treated cells 24h after irradiation with 
single or double split-doses of UVA. HaCaT cells were first treated (or not) with 10 µM  hemin for 18h 
and then incubated (or not) for 2h with 0.5 mM ALA at 37
o
C under dark condition prior to irradiation with 
single doses of 5 and 10 kJ/m
2
.  For split-dose conditions, following the first irradiation, cells were incubated for 
1h in conditioned media and then exposed to a second UVA dose of 5 kJ/m
2
. 
All control cells were treated the same except that they were either not irradiated and (or) not treated with ALA 
and hemin. MTT analysis was performed 4h after UVA irradiation. 
The results are expressed as mean ± standard deviation (n-3-5). 
*: p<0.05, significantly different from the unirradiated ALA-treated cells.     
§: p<0.05, significantly difference from irradiated ALA-treated cells.  
†: p<0.05, significantly different from the hemin-treated cells irradiated with UVA single dose of 5/0 kJ/m2. 
¥: p<0.05, significantly different from the hemin-treated cells irradiated with UVA single dose of 10/0 kJ/m
2
.
          
 
 





Porphyrins and, in particular, PPIX are thought to be very important UVA chromophores, 
since they possess a band absorption with a peak around 405-410 nm that tails within the 
UVA range and have the potential of generating 
1
O2 and other ROS upon UVA irradiation. 
Therefore for the treatment of readily accessible superficial skin lesions, ALA-PDT in the 
UVA region (320-400 nm) may be preferable to red or green wavebands, because of its 
higher efficiency. Indeed blue light in combination with ALA has been shown to be effective 
in the PDT of superficial skin lesions such as AK. Blue light that tails within the Soret band 
(410 nm) of PPIX is a powerful alternative light source to red light as it would give the 
largest cell inactivation down to about 2 mm from the surface in human skin and muscle 
tissues as well as in superficial BCC (Szeimies et al, 1995; Peng et al, 1997). 
Although compared to red light, high doses of UVA have been shown to cause mutations in 
DNA (Kvam et al, 1997), it is thought that the proposed low doses in the present study are 
unlikely to be mutagenic. Nevertheless further experiments are required to prove this point. 
Pourzand et al (1999b) have previously demonstrated that accumulating endogenous PPIX by 
exogenous ALA treatment strongly sensitises human skin fibroblasts to UVA photokilling 
(Pourzand et al, 1999b). A study by Buchczyk et al  (2001) comparing red, green and UVA 
light sources in ALA-PDT of human skin cells has further demonstrated that compared with 
red light source, UVA-based ALA-PDT was 40-fold more potent in killing cultured human 
skin fibroblasts and still 10-fold more potent than ALA-PDT with green light. The high 
cytotoxicity of UVA-based ALA-PDT relied on the efficient formation of 
1
O2 as was 
demonstrated with modulators of 
1
O2-half-life. In the present study, further evidence has been 
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provided that demonstrates that ALA-PDT with UVA is also effective in killing of human 
skin keratinocytes despite their high resistance to UVA-mediated oxidative damage and cell 
death (Pourzand and Tyrrell; 1999; Reelfs et al, 2010). Indeed previous studies from this 
laboratory have demonstrated that epidermal keratinocyte cells (including HaCaT) are 
resistant to up to high UVA doses of 750 kJ/m
2
 (see Reelfs et al, 2010), but ALA treatment 
used in this study strongly sensitises the HaCaT cells to extremely low doses of UVA within 
the range of 10-100 kJ/m
2
 (i.e. by taking into account both single and cumulative double 
UVA doses). The Sellas UVA light source used in this study has a significant peak at 405 nm 
that overlaps with the Soret band of PPIX that should almost certainly contribute to the 
efficient cell killing of ALA-treated HaCaT keratinocytes.  
 
1
O2 and H2O2 are thought to be the most important ROS generated intracellularly by UVA, 
promoting biological damage in exposed tissues via iron-catalysed oxidative reactions (Vile 
and Tyrrell, 1995). It has been shown that UVA doses at natural exposure level (i.e. 100-500 
kJ/m
2
) induce lipid peroxidation in membranes of human primary fibroblasts and 
keratinocytes via pathways involving iron and 
1
O2 (Vile and Tyrrell, 1995; Morlier et al, 
1991; Punnonen et al, 1991). The UVA-mediated increase in LIP has been shown to further 
exacerbate the peroxidative damage in cultured skin cells that may lead to the loss of cell 
membrane integrity and cell death (Zhong et al, 2004). It is anticipated that the damaging 
effect of UVA would become even more important in ALA-treated skin cells as the 
combination of artificially increased photochemical generation of 
1
O2 and other ROS by 
endogenously accumulated PPIX along with UVA-mediated increase in intracellular LI could 
potentiate the formation of highly reactive oxygen species that would trigger substantial 
peroxidative membrane damage leading to necrotic cell death. Indeed, iron „at‟ or „near‟ 
strategic targets such as cell membranes, can undergo redox cycling by reacting sequentially 
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with one electron reductants and oxidants, thereby generating toxic oxidants such as ·OH and 
lipid derived alkoxyl and peroxyl radicals, can elicit biological damage and cell death (Aust 
et al, 1985; Halliwell and Gutteridge, 1992). Therefore the simultaneous presence of LI and 
ROS generated by UVA in ALA-treated cells could be effective in therapy of superficial skin 
lesions. Nevertheless the presence of excess labile iron could decrease the level of ALA 
induced PPIX accumulation via ferrochelatase dependent conversion of PPIX to heam. It is 
clear that in the future studies the correlation of iron accumulation by UVA and the level of 
conversion of PPIX to haem have to be investigated.  
Previous studies from this laboratory have already demonstrated the impact of UVA-induced 
LI release in promoting necrotic cell death in skin fibroblasts. Furthermore, it has been 
demonstrated that iron loading of human keratinocytes with hemin or iron citrate 
substantially sensitises the human keratinocyte cells to UVA-induced necrotic cell death, as a 
result of UVA-induced increase in LIP. Indeed hemin treatment has been shown to provoke 
substantial necrosis in HaCaT cells irradiated with a low UVA dose of 100 kJ/m
2
, 1-4h 
following radiation treatment (Zhong et al, 2004). In the present study we further 
demonstrate that ALA treatment in combination with hemin further sensitises the 
keratinocytes to very low doses of UVA, presumably as a result of increase in UVA-induced 
LI release. The split-dose combination experiments carried out in the present project further 
reveal the importance of the first UVA dose to exacerbate the damage produced by the 
second UVA dose. Indeed the higher initial dose of UVA has a critical impact in determining 
the efficiency of cell killing following the second UVA dose, presumably because the level of 
first dose-mediated ROS generation and LI release directly contribute to the extent of damage 
caused by second UVA insult. Nevertheless future studies are necessary to measure the level 
of ROS production and LI released upon our experimental conditions. 
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Previous studies have demonstrated the importance of light fractionation in improving the 
efficiency of PDT of tumours (e.g. Curnow et al, 1999). Iron chelation has also been 
proposed as a mean to improve the efficiency of ALA-PDT and according to a comparative 
study carried out by Curnow and colleagues, both light dose fractionation and iron chelation, 
could significantly enhance the efficiency of ALA-PDT in the normal and neoplastic tissues 
investigated (Curnow et al, 2006). 
Figure 4.1 illustrates our proposed mechanism of cell killing by single or split-dose UVA 
irradiation in combination with ALA +/- hemin, based on the results obtained in the present 
study. The main points of this proposal are discussed below: 
- Figure 4.1A: In ALA-treated cells, the first dose of UVA not only triggers the formation of 
ROS but also promotes extensive release of LI as a result of Ft degradation which in turn 
sensitizes the cells to a second challenge dose of UVA resulting in higher necrotic cell death. 
This hypothesis is strengthened by our double split-dose combination studies showing that 
the extent of UVA-induced cell killing is dependent on the dose of the first UVA irradiation. 
When a low dose of 5 kJ/m
2
 is applied first, the overall decrease in cell viability is moderate 
after the second irradiation even with higher UVA doses of 10 or 20 kJ/m
2
. The UVA dose of 
50 kJ/m
2
 on the other hand appears to be the only dose that has effective cytotoxicity in 
ALA-treated cells both as a single dose or in combination with other doses. Nevertheless our 
results demonstrated that lower double-dose UVA combinations of 20/5, 20/10 and 20/20 
kJ/m
2
 are also highly effective cytotoxic combinations in ALA-treated cells. Therefore the 
dose combination of 20/5 could be less time consuming in clinical practice. 
- Figure 4.1B: In overnight hemin-treated cells, the Ft level is much higher than untreated 
cells (Zhong et al, 2004). So UVA-irradiation of hemin+ALA-treated cells would promote 
higher UVA-induced LI release which in turn in conjunction with generated ROS will further 
- 125 - 
 
exacerbate the  susceptibility of the cells to UVA-induced oxidative damage leading to higher 
necrotic cell death. Although our pilot study performed in this one-year MPhil project is in 
agreement with this hypothesis, in future studies it is necessary to measure the LI released 
after UVA in ALA+/- hemin-treated cells to be able to show a direct correlation between the 
amount of LI release and damage caused.  
Previous data from our laboratory have shown that hemin-mediated increase in Ft in HaCaT 
cells persists up to 48 h following treatment. This may be used as a potential intervention 
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Figure 4.1.  The proposed effect of UVA-induced iron release on ALA (+/-hemin)-treated 
HaCaT cells. 
(A). Treatment of HaCaT cells with ALA promotes an increase in the level of endogenous 
photosensitiser PPIX that sensitises the cells to UVA irradiation leading to generation of ROS and 
labile iron release as a result of Ft degradation. The generated ROS along with labile iron increase by 
UVA provokes damage to cells leading to necrotic cell death. A second UVA dose of UVA, 1h 
following the first irradiation, triggers the formation of additional ROS that in conjunction with excess 
labile iron still present within cells promote further oxidative damage to HaCaT cells leading to higher 
necrotic cell death. However future studies are necessary to clarify the extent of contribution of UVA 
irradiation and/or accumulated PPIX  to the observed cell death. 
 (B). Overnight hemin treatment of HaCaT cells promotes an increase in the level of intracellular Ft. 
ALA treatment of cells in the next day promotes an increase in the level of endogenous 
photosensitiser PPIX. The UVA irradiation of the hemin+ALA treated cells not only promotes the 
formation of ROS via PPIX but also leads to substantial increase in labile iron as a result of 
proteolytic degradation of highly accumulated Ft. This combination provokes substantial damage to 
cells leading to high necrotic cell death. 
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Topical ALA-PDT is an effective method for treating sun-damaged skin with multiple AK 
(Morton et al, 2002). The major side-effect of PDT is the pain experienced during the 
treatment (Morton et al, 2002). Management of treatment-related pain remains still a 
considerable challenge in patients (Morton et al, 2002). Further optimization of the light 
source, dose and period of treatment therefore seems crucial to alleviate pain. The pilot study 
carried out in this MPhil project provides strong evidence that applying short pulses of UVA 
radiation to ALA-treated skin cells is a fast and effective approach to promote cell death. 
Therefore applying split low doses of UVA radiation in combination with ALA may be used 
as an effective intervention strategy to decrease considerably the time of radiation treatment 
and therefore reduce the pain associated with prolonged conventional topical ALA-PDT of 
AK lesions using LED. 
 
Our proposed methodology responds to the urgent need of finding alternative ways to 
alleviate ALA-PDT-related pain, by reducing to minimum the period of radiation. Indeed our 
results demonstrate that in ALA-treated skin cells, the low split- dose UVA radiation strategy  
provides effective result with 2 short pulses of 10-50 kJ/m
2
. In a clinical setting, typically 
with a fluence rate of 150 W/cm
2
, and the distance of 30 cm, the irradiation time with these 
UVA doses will be between 30 seconds to 2 min for all doses used. So such short treatments 
are likely to make the pain more tolerable. In comparison, for example in Bath Royal United 
Hospital, the MAL-PDT of AK is carried out with an LED (631 nm) light source for 9 min to 
achieve a dose of 37 J/cm
2
 with a distance of 5-8 cm. The potentially effective and specially 
the fast damaging consequence of split low dose UVA protocol, when compared to prolonged 
LED radiation treatment, highlights our proposed strategy as a rapid and simple means to 
improve the effectiveness of conventional ALA-PDT of skin lesions while decreasing 
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considerably the time of irradiation that is directly related to the extent of pain endured by 
patients.  
However, this treatment can only be suggested for the most superficial lesions and not for all 
currently licensed applications. Extensive follow ups however may be required to monitor the 
carcinogenic risk of the treatment. One drawback of the proposed treatment would be that the 
patients will spend more time in clinics and that would decrease the number of patients 
treated per day. 
The work outlined here addresses further the suitability of UVA low split dose strategy as a 
possible therapy for epidermal diseases, including non-melanoma skin cancer (NMSC). 
Based on our pilot study presented in this MPhil work, the effectiveness of UVA split-dose 
strategy could be further tuned in the future studies using a series of cultured AK and SCC 
cell lines in both monolayer and 3-dimensional organotypic raft cultures. The best split dose 
protocol could then be evaluated in an open pilot study in collaboration with dermatologists 
looking at a few patients for instance with symmetrical AK lesions.   The split dose UVA-
ALA-PDT might have also a future in treatment of psoriasis, as at present the topical ALA-
PDT clinical studies with psoriatic patients is often interrupted because of the severe pain 
experienced by patients. So decreasing the time of ALA-PDT with split-dose UVA strategy 
might provide a powerful alternative to present modalities. Psoralen with UVA has already 
been used for treatment of psoriasis but this treatment is accompanied with severe side 
effects. Short term side effects are increased photosensitivity and gastrointestinal and ocular 
side effects when administered orally, also redness, swelling and occcational blister 
formation, fever and general malaise. Long term side effects are promotional skin cancer 
(Honigsmann et al, 1982; Honigsmann et al, 2001; Cox et al, 1987). Furthermore while in 
general the PUVA therapy doses are between 5-10 kJ/m
2
, because of the necessity of 
repeated therapies, the cumulative UVA doses in PUVA could reach values up to 250-500 




that is detrimental to patients given the DNA damaging nature of psoralen (e.g. Lai et 
al, 2008; Honigsmann, 2001).In comparison our UVA split-dose strategy is likely to be much 
more effective with two low UVA doses especially that such UVA doses would be much less 
toxic with negligible cumulative effect. 
As previously discussed, due to the proposed low doses of UVA applied in these 
experiments, the risk of UVA causing carcinogenicity is very low. It could be argued that the 
more effective ALA-PDT by UVA light could be more painful due to high generation of 
ROS, thus more ROS formation could generate more pain in treated patients. However to our 
knowledge there is no evidence that ROS formation in ALA-PDT is directly related to the 
pain experienced by the patients. For example blue light (whithin UVA range), is currently 
used in the US for treating AK and no study has directly related the ALA-PDT mediated pain 
to the choice of blue light. Nevertheless the relationship beween ROS formation and the pain 
indured by the patients during ALA-PDT by UVA may be clinically investigated in the 
future.  
The potential of fractionated illumination with red light in ALA-PDT has already been 
demonstrated in a range of preclinical studies in a variety of clinical models (e.g. de Bruijn et 
al, 1999; Robinson et al, 2000).These studies show that fractionated PDT results in 
significantly higher responses compared with PDT performed with a single illumination (e.g. 
de Bruijn et al, 1999; Robinson et al, 2000). Such studies have also shown the importance of 
the time interval between ALA application and the first light fraction and its relation to the 
synthesis of PPIX. For example Robinson et al (2003) have shown that a fractionated 
illumination scheme in which a cumulative fluence of 100 J/cm
2
 red light is delivered in two 
equal light fractions separated by a dark interval of 2h is considerably more effective in 
ALA-PDT of SHK1 HR hairless mouse than one single dose. They have further demonstrated 
that the efficacy of such a scheme is further increased if the fluence of the first light fraction 
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is reduced to 5 J/cm
2
, since the photobleaching of PPIX during the first illumination and its 
re-synthesis in dark interval would contribute to the effectiveness of the second dose. 
Although in our study, we did find that a lower first dose was not effective in UVA-based 
split–dose ALA-PDT of HaCaT cells, we could not exclude the possibility that the 
effectiveness of our higher UVA split-dose combinations is due to re-synthesis of PPIX 
during the 1h dark interval. So it is necessary that in future studies the PPIX level as well as 
the kinetics of PPIX fluorescence be investigated under our experimental conditions. 
However they have also found that these regimes do not work with MAL, which is the 
licensed drug in the UK. 
 
Besides the influence of the fluence rate of the individual light fractions, the time interval 
between light fractions has been shown to be critical in ALA-PDT with red light. For 
example enhanced ALA-PDT response is achieved if two lights fractions are delivered 4 and 
6h after the application of ALA, separated by a 2h dark interval (de Bruijn et al, 2006). In a 
recent clinical study performed by de Haas et al (2008) involving 552 patients with sBCC, 
nBCC, BD and AK, a two fold illumination scheme was carried out using three different light 
sources (i.e. one diode laser at 630 nm and two broadband light sources with spectral output 
of 590-650 nm and 633 nm with a bandwidth of 20 nm, respectively). The protocol involved 
the topical application of 20% ALA for 4 h followed by two light fractions of 20 and 80 
J/cm
2
 separated by a 2 h interval. After an average follow up of 12-24 months, an overall 
complete response of 95% was seen for all lesions.  So based on these findings, it is 
necessary that in future studies, comparative studies be carried out to evaluate the impact of 
the length of ALA treatment as well as the time interval between UVA split doses in 
improving the efficiency of UVA-split dose ALA-PDT in our experimental model. Such 
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studies are necessary to establish standard protocols that then could be evaluated in animal 
studies in order to find out the most efficient conditions for the use in clinic.  
 
Finally, while our pilot study presented here provides experimental evidence of the high 
effectiveness of split-dose UVA strategy for ALA-PDT, in future studies it will be necessary 
to repeat these data with MAL, as ALA is not approved in Europe for PDT of skin superficial 
lesions such as AK since it has not being patented. The further tuning of the UVA-split 
protocols involving topical MAL or ALA in animal studies, could then be tested in pilot 
clinical studies involving patients with superficial AK lesions. Although long follow-up times 
will be required to assess potential procarcinogenic effects, these comparative studies may 
provide further insights into the effectiveness of either treatments for AK as well as the 
suitability of ALA- or MAL-based PDT in decreasing the pain experienced by the patients 
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